Giant Cell Arteritis

On this page

Quick Reference

RxDrug of choiceprednisone 40-60 mg/day orally or IV for acute flare; for organ-threatening disease (visual loss), IV methylprednisolone 1 g/day for 3 days. Adjunctive tocilizumab 162 mg SC weekly with 26-week prednisone taper for sustained remission.

AltAlternativesmethotrexate 15-25 mg PO/SC weekly; upadacitinib 15 mg PO daily; abatacept 10 mg/kg IV monthly; mavrilimumab 150 mg SC every 2 weeks (investigational).

⊘AvoidAnti-TNF agents (infliximab, adalimumab, etanercept); non-dihydropyridine CCBs (diltiazem, verapamil), exacerbate heart failure if present; live vaccines during high-dose immunosuppression; methotrexate in pregnancy (contraindicated).

DxTest of choiceHigh-resolution ultrasound of temporal and axillary arteries (halo sign), first-line imaging with 88% sensitivity and 96% specificity. Temporal artery biopsy if ultrasound equivocal or negative but high suspicion.

ScKey score2022 ACR/EULAR classification criteria: age ≥50 mandatory; score ≥6 points (positive biopsy/halo +5, ESR≥50 or CRP≥10 +3, sudden visual loss +3, +2 for each of morning stiffness, jaw/tongue claudication, new headache, scalp tenderness, temporal artery abnormality, bilateral axillary involvement, aortic FDG-PET activity).

→When to referUrgent rheumatology referral for all suspected GCA; same-day ophthalmology referral for acute visual loss; consider vascular surgery for large-vessel stenosis or aneurysm.

Giant cell arteritis is a medical emergency requiring immediate high-dose glucocorticoids to prevent blindness and stroke. Early use of steroid-sparing agents (tocilizumab or methotrexate) reduces cumulative glucocorticoid exposure and long-term morbidity. Aortic imaging at diagnosis and at 5 years is essential for detecting aneurysm.

Giant cell arteritis (GCA) is a granulomatous large-vessel vasculitis that preferentially affects the aorta and its extracranial branches, occurring almost exclusively in adults aged ≥50 years. It is a medical emergency because of its potential to cause permanent vision loss (11-15% of patients), cerebrovascular ischemic events, and aortic dissection. The disease encompasses cranial and large-vessel phenotypes, with the 2022 ACR/EULAR classification criteria (score ≥6) providing a validated framework. Immediate high-dose glucocorticoids are the cornerstone of acute management, and adjunctive therapy with tocilizumab or methotrexate reduces cumulative steroid exposure and improves outcomes.

Overview and Recommendations

Background

•Giant cell arteritis (GCA) is a granulomatous large-vessel vasculitis that preferentially affects the aorta and its extracranial branches, occurring almost exclusively in adults aged 50 years and older. Also called Horton disease or temporal arteritis, it is now recognized as a spectrum including cranial and large-vessel phenotypes.
•The disease is a medical emergency because of its potential to cause permanent vision loss in 11-15% of patients, cerebrovascular ischemic events (pooled prevalence 4%), and aortic dissection (15-year relative risk 6.86 compared to the general population). Incidence peaks at 23.1 per 100,000 person-years in those aged 80-84 years, with a female predominance (female-to-male ratio ~2.5:1).
•Two main clinical phenotypes dominate: cranial GCA, which involves the temporal arteries and presents with headache, scalp tenderness, jaw claudication, and vision loss; and large-vessel GCA (LV-GCA), characterized by aortic, subclavian, and axillary artery inflammation, often presenting with limb claudication and constitutional symptoms. A mixed phenotype is also recognized, and a subset of patients with polymyalgia rheumatica (PMR) have subclinical GCA detected by imaging.
•The 2022 ACR/EULAR classification criteria (mandatory age ≥50 years) assign points for positive temporal artery biopsy or halo sign on ultrasound (+5), ESR ≥50 mm/hr or CRP ≥10 mg/L (+3), sudden visual loss (+3), and various clinical features (jaw claudication, new temporal headache, scalp tenderness, etc.) at +2 each. A cumulative score of ≥6 classifies a patient as having GCA, with sensitivity 87% and specificity 94.8%.
•The pathogenic cascade begins with activation of resident adventitial dendritic cells via Toll-like receptors, recruiting CD4+ T cells that polarize into Th17 cells (driven by IL-6, IL-1β, IL-23) and Th1 cells (driven by IL-12). The IL-6/Th17/IL-17 axis fuels systemic inflammation, while the IL-12/Th1/IFN-γ axis orchestrates granulomatous inflammation and vascular wall damage. The former is highly glucocorticoid-sensitive; the latter is steroid-resistant, explaining why high-dose corticosteroids rapidly suppress systemic symptoms but may not fully control vessel-wall inflammation.
•Risk factors include female sex, Northern European ancestry, age ≥70, and prior herpes zoster infection (especially ophthalmic). Type 2 diabetes is paradoxically protective (OR 0.75). Clonal hematopoiesis (DNMT3A, TET2 mutations) is present in 55-61% of GCA patients and may define a higher-risk subgroup.

Evaluation

•Suspect GCA in any patient ≥50 years with new-onset headache (especially temporal, unilateral or bilateral, aching or throbbing), scalp tenderness, jaw claudication (the single strongest clinical predictor), or unexplained constitutional symptoms (fever, weight loss, malaise).
•Ask about transient monocular vision loss (amaurosis fugax), diplopia, or sudden visual loss, these are ophthalmologic emergencies requiring immediate action. Also inquire about limb claudication (arms or legs) and symptoms of polymyalgia rheumatica (morning stiffness in shoulders, neck, hips).
•Examine the temporal arteries for tenderness, nodularity, thickening, or pulselessness; a firm, beaded cord is pathognomonic but often absent. Check for blood pressure asymmetry >10 mm Hg (suggests large-artery stenosis), and perform ophthalmologic examination (afferent pupillary defect, optic disc edema, pallor) if visual symptoms are present.
•Order urgent laboratory studies: ESR, CRP, complete blood count, and comprehensive metabolic panel. ESR ≥50 mm/hr or CRP ≥10 mg/L supports the diagnosis but up to 10% of biopsy-proven GCA patients have normal levels.
•Perform high-resolution ultrasound of the temporal and axillary arteries as the first-line imaging test (EULAR 2023 recommendation). The halo sign, a non-compressible, hypoechoic, concentric wall thickening, has pooled sensitivity 88% and specificity 96% for GCA. Scanning should occur within days of starting glucocorticoids, as the halo sign resolves within 2-4 weeks of therapy.
•If ultrasound is equivocal or negative but clinical suspicion remains high, proceed to temporal artery biopsy (TAB) or MRI of the scalp arteries. TAB has a sensitivity of only ~69% (giant cells, fragmentation of internal elastic lamina, mononuclear infiltration); a negative biopsy does not rule out GCA.
•Consider [18F]-FDG-PET/CT when large-vessel involvement is suspected or cranial imaging is equivocal. The GAPS study reported sensitivity 71% and specificity 91% against clinical diagnosis, with a negative predictive value of 98%. FDG-PET also detects incidental infections or malignancies and aortitis.
•Apply the 2022 ACR/EULAR classification criteria to standardize diagnosis: age ≥50 mandatory; positive TAB or halo sign (+5), ESR ≥50 or CRP ≥10 (+3), sudden visual loss (+3), morning stiffness in shoulders/neck (+2), jaw or tongue claudication (+2), new temporal headache (+2), scalp tenderness (+2), temporal artery abnormality on exam (+2), bilateral axillary involvement on imaging (+2), FDG-PET activity throughout aorta (+2). Score ≥6 classifies as GCA.
•Also consider alternative diagnoses: ANCA-associated vasculitis (check ANCA if atypical features like renal, pulmonary, or ENT involvement), VEXAS syndrome (consider in older men with treatment-refractory GCA-like symptoms, cytopenias, and bone marrow vacuoles), and other causes of headache or systemic inflammation.
•Assess disease activity using clinical examination and inflammatory markers. The OMERACT GCA Ultrasonography Score (OGUS) quantifies intima-media thickness and predicts relapse risk (IRR 1.85 per 1-point increase). For patients on tocilizumab, note that CRP normalizes rapidly regardless of disease activity, so clinical assessment is paramount.

Management

•For patients without visual loss or organ-threatening features, start 40-60 mg/day orally or IV equivalent. For patients with acute visual loss or amaurosis fugax, give IV 1 g/day for 3 days, followed by high-dose oral taper. Do not delay therapy for diagnostic tests, biopsy or imaging can be performed within 1-2 weeks of starting glucocorticoids without loss of diagnostic sensitivity.
•Begin glucocorticoid taper once the flare is controlled. The ACR 2021 guideline recommends a taper over 6-12 months; a 26-week taper is feasible when a steroid-sparing agent is used. Monitor for glucocorticoid adverse effects: blood glucose, blood pressure, bone density, and infection risk.
•Add a glucocorticoid-sparing agent in patients with refractory or relapsing disease, or those at high risk for glucocorticoid toxicity. First-line options: 162 mg SC weekly (or 8 mg/kg IV monthly) plus a 26-week prednisone taper, or 15-25 mg PO/SC weekly.
•Tocilizumab: In the GiACTA trial, sustained glucocorticoid-free remission at week 52 was 56% (weekly) vs 14% (placebo+26-week taper), NNT = 2.4. Continue for at least 12 months; after discontinuation, approximately 50% will relapse within 1-2 years. Monitor for neutropenia (hold if ANC <1000/μL), elevated transaminases (hold if >3× ULN), and hyperlipidemia (check lipid panel at 4-8 weeks, then every 6-12 months).
•Methotrexate: Modest glucocorticoid-sparing effect; less effective than tocilizumab. Monitor for toxicity, especially in elderly patients on diuretics, PPIs, or with low eGFR. Start with folic acid 1 mg daily to reduce toxicity.
•Alternative second-line agents: 15 mg PO daily with 26-week taper (SELECT-GCA: sustained remission 46.4% vs 29.0%, NNT 5.7; use with caution in patients with high cardiovascular risk); 10 mg/kg IV on days 1, 15, 29, then monthly (median remission duration 9.9 vs 3.9 months); 150 mg SC every 2 weeks (investigational, reduced flare risk by 62% in phase 2).
•Do not use anti-TNF agents (infliximab, adalimumab, etanercept), they have shown no benefit in GCA. Do not routinely use antiplatelet or anticoagulant therapy for GCA itself unless indicated for other reasons. Do not rely on CRP/ESR alone to guide therapy in tocilizumab-treated patients (92% of flares occur with normal CRP).
•Monitor for disease-driven complications: aortic aneurysm (2-fold risk; 4.5-fold faster growth than degenerative aneurysms), perform CT or MR angiography of thoracic aorta at diagnosis and at 5 years. Cerebrovascular events (3.96% of patients, predominantly vertebrobasilar), manage cardiovascular risk factors aggressively.
•Prevent glucocorticoid-induced osteoporosis: all patients starting ≥7.5 mg/day prednisolone for ≥3 months should receive calcium (1000-1200 mg/day), vitamin D (800 IU/day), and a bisphosphonate (alendronate 70 mg weekly or zoledronic acid 5 mg annually).
•Ensure vaccination: recombinant zoster vaccine (before or during glucocorticoid tapering, ideally ≥2 weeks before immunosuppression), annual influenza, pneumococcal, and SARS-CoV-2 boosters. Live-attenuated vaccines are contraindicated during high-dose immunosuppression.
•Refer to rheumatology urgently for all suspected GCA. For acute visual loss, refer to ophthalmology same day. Consider multidisciplinary care for large-vessel involvement (vascular surgery, cardiology). Discharge criteria: patient stable on therapy, no acute visual loss, and clear plan for glucocorticoid taper and monitoring.

Board Review — High Yield

•Jaw claudication, the single strongest clinical predictor of GCA; positive likelihood ratio >10.
•Halo sign on ultrasound, non-compressible, hypoechoic, concentric wall thickening of temporal/axillary arteries; sensitivity 88%, specificity 96%.
•2022 ACR/EULAR criteria, age ≥50 mandatory; score ≥6 = classify as GCA; positive TAB or halo sign = +5 points.
•IL-6/Th17 vs IL-12/Th1 axis, the former is glucocorticoid-sensitive (systemic inflammation), the latter is steroid-resistant (vessel wall damage); explains why tocilizumab targets IL-6 but relapses may occur via Th1 pathway.
•GiACTA trial, tocilizumab 162 mg SC weekly + 26-week prednisone taper: 56% sustained glucocorticoid-free remission at week 52 vs 14% with placebo; NNT 2.4.
•Aortic aneurysm risk, 2-fold increase in GCA; 4.5-fold faster growth than degenerative aneurysms; CT/MR angiography at diagnosis and 5 years.
•Tocilizumab safety, neutropenia, transaminitis, hyperlipidemia; monitor ANC, ALT/AST, lipids; hold if ANC <1000/μL or ALT >3× ULN.
•What NOT to do, do not use anti-TNF agents; do not use antiplatelet/anticoagulation for GCA alone; do not rely on CRP/ESR in tocilizumab-treated patients.
•VEXAS syndrome, consider in older men with treatment-refractory GCA-like symptoms, cytopenias, and bone marrow vacuoles (somatic UBA1 mutation).
•Vertebrobasilar stroke, 62.3% of cerebrovascular events in GCA; mortality doubled in patients with CVA (18% vs 8.8%).

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸GCA is the most common primary systemic vasculitis in adults over 50, with a predilection for the aorta and extracranial arteries.
▸The 2022 ACR/EULAR classification criteria use a points-based system (threshold ≥6) and are intended for research, but demonstrate high sensitivity and specificity in clinical practice.
▸Two main clinical phenotypes, cranial and large-vessel (extracranial), have distinct presentations, outcomes, and treatment responses.

HY High Yield: Vision loss in GCA can be permanent; up to 15% of patients experience it, often within the first weeks of untreated disease.

! Warning: Do not delay high-dose glucocorticoids while awaiting temporal artery biopsy or imaging, treatment should not be postponed for diagnostic confirmation.

Giant cell arteritis (GCA), also called temporal arteritis, is an inflammatory autoimmune disease of large blood vessels. It is the most common type of systemic vasculitis affecting adults. Symptoms may include headache, — Giant cell arteritis — Giant cell arteritis (GCA), also called temporal arteritis, is an inflammatory autoimmune disease of large blood vessels. It is the most common type o...Wikipedia ↗

Giant cell arteritis (GCA) is a granulomatous large-vessel vasculitis that preferentially affects the aorta and its extracranial branches, occurring almost exclusively in adults aged 50 years and older ^[24]^D5^[25]^D5. Also called Horton disease, temporal arteritis, cranial arteritis, or granulomatous giant cell arteritis, the disease is now recognized as a spectrum that includes both cranial and large-vessel (extracranial) phenotypes ^[23]^D5^[24]^D5^[29]^D5.

Clinical Phenotypes

Two main patterns dominate: cranial GCA, which involves the temporal arteries and presents with headache, scalp tenderness, jaw claudication, and vision loss; and large-vessel GCA (LV-GCA), characterized by aortic, subclavian, and axillary artery inflammation, often presenting with limb claudication, constitutional symptoms, and fewer cranial features ^[7]^B2b^[21]^B3b^[24]^D5. A mixed phenotype is also recognized, and a subset of patients with polymyalgia rheumatica (PMR) have subclinical GCA detected by imaging, which carries a higher relapse risk ^[12]^B2b^[30]^B2b^[36]^B2b.

Classification Criteria

In 2022, the American College of Rheumatology and EULAR published updated classification criteria for GCA, intended for research ^[10]^B2b^[16]^B2b. Age ≥50 years at diagnosis is mandatory. Points are assigned as follows:

Criterion	Points
Positive temporal artery biopsy or halo sign on ultrasound	+5
ESR ≥50 mm/hr or CRP ≥10 mg/L	+3
Sudden visual loss	+3
Morning stiffness in shoulders/neck, jaw or tongue claudication, new temporal headache, scalp tenderness, temporal artery abnormality on exam, bilateral axillary involvement on imaging, or FDG-PET activity throughout the aorta (each)	+2

A cumulative score of ≥6 classifies a patient as having GCA ^[10]^B2b^[16]^B2b. In validation cohorts, the criteria achieved an AUC of 0.91 (95% CI 0.88-0.94), sensitivity 87.0% (95% CI 82.0-91.0%), and specificity 94.8% (95% CI 91.0-97.4%) ^[16]^B2b. Though designed for classification, they perform well diagnostically in clinical practice (sensitivity 92.6%, specificity 71.8% in one fast-track cohort) ^[38]^B2b.

Clinical Significance

GCA is a medical emergency because of its potential to cause permanent vision loss (reported in 11-15% of cohorts), cerebrovascular ischemic events (pooled prevalence 4%), and aortic dissection (15-year relative risk 6.86 compared to the general population) ^[8]^B2b^[28]^A1a^[39]^A1a. The incidence peaks at 23.1 per 100 000 person-years in those aged 80-84 years, with a female predominance (10.1 vs 4.8 per 100 000 in men) ^[36]^B2b. Mortality is increased, with standardized mortality ratios rising over time (1.92 in 2018) ^[20]^B2b.

Pearl: In any patient over 50 with new headache, jaw claudication, or unexplained vision loss, suspect GCA immediately; the 2022 ACR/EULAR criteria can standardize classification, but the clinical diagnosis remains the gold standard, do not delay empiric high-dose glucocorticoids while awaiting confirmatory testing.

Pathophysiology & Mechanism

▸GCA pathogenesis is initiated by TLR-activated adventitial dendritic cells that polarize CD4+ T cells into Th17 (IL-6-driven) and Th1 (IL-12-driven) effector subsets, creating a dual cytokine hierarchy with differential glucocorticoid sensitivity.
▸Genetic susceptibility loci (HLA, MFGE8, VTN, CCDC25, VLDLR) implicate antigen presentation, angiogenesis, NETosis, and LDL cholesterol metabolism, while trained immunity programs in monocytes sustain IL-6 overproduction.
▸Treg dysfunction (Foxp3Δ2, IL-17 secretion) and persistent vascular inflammation via the steroid-resistant IL-12/IFN-γ axis underlie the high relapse rate and the need for targeted therapies beyond IL-6 blockade.

HY High Yield: The IL-6/Th17 axis is glucocorticoid-sensitive and drives systemic inflammation; the IL-12/Th1/IFN-γ axis is steroid-resistant and drives vascular wall damage. This dichotomy explains why tocilizumab targets the former but relapses may occur via the latter, and why imaging often reveals persistent vessel inflammation despite normalized acute-phase reactants [58,62].

From the classification of GCA as a granulomatous large-vessel vasculitis, the pathogenic cascade begins with a breach of immune tolerance in the vessel wall. The inciting event is activation of resident adventitial dendritic cells (DCs) via Toll-like receptors (TLRs), likely triggered by pathogen-associated molecular patterns, varicella zoster virus has been proposed as a candidate trigger, though evidence is geographically heterogeneous (pooled LogOR 1.03, 95%) ^[49]^A1a^[53]^D5. Activated DCs then recruit and polarize CD4⁺ T cells into two dominant effector subsets: Th17 cells (driven by IL-6, IL-1β, IL-23) and Th1 cells (driven by IL-12) ^[62]^D5^[65]^D5. This polarization establishes a dual cytokine hierarchy: the IL-6/Th17/IL-17 axis fuels systemic inflammation and acute-phase responses, while the IL-12/Th1/IFN-γ axis orchestrates granulomatous inflammation and vascular wall damage ^[58]^D5^[62]^D5. Notably, the IL-6/Th17 pathway is highly glucocorticoid-sensitive, whereas the IL-12/IFN-γ axis is steroid-resistant, explaining why high-dose corticosteroids rapidly suppress systemic symptoms but may not fully control vessel-wall inflammation ^[62]^D5.

Effector Mechanisms and Vascular Remodeling

Activated Th1 and Th17 cells secrete IFN-γ and IL-17, which recruit monocytes and promote their differentiation into pro-inflammatory macrophages and multinucleated giant cells ^[33]^D5^[65]^D5. Macrophages produce matrix metalloproteinases (MMP-9) that degrade the internal elastic lamina, enabling transmural infiltration and vascular remodeling ^[51]^D5^[65]^D5. Concurrently, vascular smooth muscle cells and fibroblasts undergo phenotypic switching to myofibroblasts, proliferating and migrating into the intima to cause concentric intimal hyperplasia, luminal stenosis, and ultimately tissue ischemia ^[44]^D5^[65]^D5. This remodeling is amplified by neoangiogenesis from the vasa vasorum, driven by vascular endothelial growth factor (VEGF) and other angiogenic factors ^[40]^B3b^[65]^D5.

Genetic and Immunometabolic Susceptibility

Genome-wide association studies have identified several risk loci that illuminate pathogenic pathways. The HLA class II region shows the strongest association, implicating antigen presentation ^[40]^B3b^[41]^B3b. Three novel loci, MFGE8 and VTN (0.79-0.89), both involved in angiogenesis, and CCDC25 (1.12-1.25), linked to neutrophil extracellular trap (NET) formation, highlight the roles of vascular repair and innate immune effector mechanisms ^[40]^B3b. The VLDLR locus is also associated, and Mendelian randomization suggests a causal effect of LDL cholesterol on GCA risk (OR 1.21 per 1 SD increase) ^[41]^B3b. Beyond genetics, myelomonocytic cells in GCA activate trained immunity programs, characterized by enhanced glycolysis, glutaminolysis, and permissive epigenetic changes, that sustain exaggerated IL-6 production and pro-inflammatory activation ^[57]^C4.

Treg Dysfunction and the IL-6 Axis

Active GCA features a dysfunctional regulatory T cell (Treg) compartment: Tregs are hypoproliferative, express a hypofunctional Foxp3Δ2 isoform, and secrete IL-17, acquiring a pathogenic Th17-like phenotype ^[46]^B2b^[52]^D5. This imbalance is driven by excess IL-6, which suppresses Treg suppressive capacity while promoting Th17 differentiation. IL-6 receptor blockade with corrects these abnormalities, restoring Treg proliferation, activation, and trafficking markers (CCR4, CTLA-4), and reduces STAT3 phosphorylation in vascular lesions ^[45]^D5^[46]^B2b. However, tocilizumab does not abrogate all inflammatory pathways; in some specimens it increases STAT1 phosphorylation and STAT1-dependent chemokines (CXCL9, CXCL10), suggesting an escape mechanism that may explain why nearly half of patients fail to maintain glucocorticoid-free remission ^[45]^D5.

Persistence of Vascular Disease

Despite clinical remission, temporal arteries and aortas of treated patients often show persistent immune-mediated abnormalities ^[44]^D5. This may reflect the steroid-resistant IL-12/Th1/IFN-γ axis and the contribution of stromal cells, fibroblasts and myofibroblasts, that act as non-immune orchestrators of chronicity ^[44]^D5^[58]^D5. The discrepancy between systemic inflammation (IL-6-driven) and vascular wall inflammation (IFN-γ-driven) poses a major challenge for monitoring and therapy ^[58]^D5.

Pearl: The IL-6/Th17 axis is glucocorticoid-sensitive and drives systemic inflammation, whereas the IL-12/Th1/IFN-γ axis is steroid-resistant and drives vascular wall damage, this dichotomy explains why tocilizumab targets the former but relapses may occur via the latter, and why imaging often reveals persistent vessel inflammation despite normalized acute-phase reactants ^[58]^D5^[62]^D5.

Key Genetic Loci Associated with Giant Cell Arteritis Susceptibility

Locus	Variant	OR (95% CI)	Implicated Pathway	Reference
HLA class II	Multiple	Strongest association	Antigen presentation	^[40]^B3b^[41]^B3b
MFGE8	rs8029053	1.19 (1.12-1.26)	Angiogenesis	^[40]^B3b
VTN	rs704	0.84 (0.79-0.89)	Angiogenesis	^[40]^B3b
CCDC25	rs11782624	1.18 (1.12-1.25)	Neutrophil extracellular traps (NETs)	^[40]^B3b
PLG	-	-	Fibrinolysis / matrix remodeling	^[40]^B3b
VLDLR	rs7044155	- (T allele protective)	LDL cholesterol metabolism	^[41]^B3b

Epidemiology, Etiology & Risk Factors

▸Incidence peaks at age 80-84 years, with a female-to-male ratio of ~2.5:1 and a strong Northern European ancestry gradient.
▸Type 2 diabetes is inversely associated with GCA risk (OR 0.75), while prior herpes zoster (especially ophthalmic) and a history of cardiovascular disease increase risk.
▸Clonal hematopoiesis (DNMT3A, TET2 mutations) is present in over half of GCA patients, and TET2/JAK2 variants identify a higher-risk subset.

Dx Diagnostic Essentials: The combination of female sex, age ≥70, Northern European ancestry, and a history of herpes zoster ophthalmicus should raise suspicion for GCA in patients with new-onset headache or systemic symptoms.

HY High Yield: Type 2 diabetes is inversely associated with GCA (OR 0.75), but this should not lower suspicion in a diabetic patient with classic symptoms.

From the vascular inflammation just described, the of giant cell arteritis (GCA) emerges as a disease of the elderly, with a strong female predominance and a striking geographic gradient. The annual incidence among persons aged ≥50 years ranges from 7.4 to 25 per 100,000 in population-based studies, with the highest rates reported in Scandinavia and Minnesota (16.8 per 100,000 in southern Norway ^[89]^B2b; 25 per 100,000 in Ontario, Canada ^[96]^B2b) and lower rates in southern Europe (7.4 per 100,000 in Spain ^[36]^B2b). Prevalence increases with age, peaking in the 80-84 year age group (23.1 per 100,000 in Spain ^[36]^B2b), and is consistently higher in women (female-to-male ratio ~2.5:1; age-standardized incidence 31 vs 15 per 100,000 in Canada ^[96]^B2b). The disease is rare before age 50 and preferentially affects persons of northern European ancestry, with lower rates in Asian, African, and Hispanic populations ^[99]^D5.

Temporal Trends

Incidence rates have remained largely stable over the past several decades, but the cumulative incidence of large-artery involvement has risen markedly: from 14.8% at 15 years in 1950-1974 to 49.2% in 2000-2016 (HR 3.48, 95% CI 1.67-7.27) ^[105]^B2b. This increase likely reflects improved imaging detection rather than a true biologic shift. The 15-year risk of or dissection in GCA is 11.2-fold higher than the general population (RR 11.2) ^[8]^B2b, and the risk of aortic aneurysm/dissection carries a standardized mortality ratio of 2.63 (95% CI 1.78-3.73) ^[70]^B2b.

Risk Factors

Factor	Odds Ratio / Hazard Ratio	Evidence Level
Female sex	2.1 (incidence ratio)	2b ^[96]^B2b
Age ≥70 years	Incidence 4-fold higher vs 50-59 years	2b ^[36]^B2b
Northern European ancestry	Not quantified (descriptive)	5 ^[99]^D5
Type 2 diabetes (inverse)	OR 0.75 (95% CI 0.61-0.93)	2a ^[79]^B2a
History of cardiovascular disease	OR 1.28 (95% CI 1.18-1.38)	2a ^[79]^B2a
Any prior infection	IRR 1.26 (95% CI 1.16-1.36)	3b ^[77]^B3b
Clonal hematopoiesis (DNMT3A, TET2)	OR not reported; prevalence 34% vs 18% in controls	4 ^[81]^C4
Higher C4B copy number (male)	OR 1.23 (95% CI 1.07-1.42)	3b ^[85]^B3b

Type 2 diabetes is paradoxically protective (OR 0.75), while a history of cardiovascular disease increases risk ^[79]^B2a. The strongest infectious trigger is , especially with ophthalmic involvement (HR 3.09) ^[101]^B2b, though the absolute risk remains low (49.9 vs 16.2 per 100,000 person-years) ^[101]^B2b. Prior infections in general modestly increase risk (IRR 1.26), with a dose-response gradient (2-4 infections: IRR 1.60; ≥5 infections: IRR 2.18) ^[77]^B3b.

Seasonal Variation

A meta-analysis of 19 studies (39,829 patients) found no overall seasonal pattern (pooled seasonal incidence risk ratio 1.08, 95% CI 0.99-1.17), but a warm-season predominance emerged in locations south of latitude 45.8°N (pooled SIRR 1.18, 95% CI 1.09-1.28) ^[108]^B2a. This suggests latitude modulates environmental triggers.

Genetic and Clonal Drivers

Clonal hematopoiesis of indeterminate potential (CHIP), particularly DNMT3A and TET2 mutations, is present in 55-61% of GCA patients (vs 18-59% of age-matched controls) and is independently associated with age and vasculitis (standardized B=0.46 for vasculitis vs 0.96 for age) ^[81]^C4^[103]^B2b. TET2- and JAK2-mutated GCA may define a higher-risk cluster with worse prognosis ^[103]^B2b. Genome-wide association studies have identified HLA variants and non-HLA loci (IL17A, IL22RA1, ATP2A2) that stratify patients into four clinical subgroups (cranial-predominant, mixed, extracranial, ischemic/occlusive) ^[82]^B3b. Complement C4B copy number is a male-specific risk factor (OR 1.23) ^[85]^B3b.

Pearl: In patients ≥50 years with new-onset headache, jaw claudication, or unexplained fever, the combination of female sex, Northern European ancestry, and a prior episode of herpes zoster (especially ophthalmic) should raise the pretest probability for GCA to >20%, justifying urgent diagnostic workup ^[17]^B2b^[101]^B2b.

Clinical Presentation

▸Jaw claudication is the strongest clinical predictor of GCA, with high certainty of effect in meta-analysis.
▸Permanent vision loss occurs in approximately one in six patients and requires immediate high-dose glucocorticoids.
▸Large-vessel involvement (extracranial phenotype) is present in 20% of patients at diagnosis and is often missed without imaging.

! Warning: Any acute visual loss in a patient >50 years should be treated as GCA until proven otherwise; delay in glucocorticoid therapy increases the risk of permanent blindness [100].

With an annual incidence of 7.42 per 100,000 persons ≥50 years in Spain ^[36]^B2b, GCA declares itself through two broad clinical axes: cranial ischemic symptoms and large-vessel inflammation, often accompanied by constitutional features and the overlapping syndrome of polymyalgia rheumatica (PMR). The onset is typically subacute over days to weeks, though symptoms can escalate abruptly, especially when vision is threatened ^[100]^D5.

Presenting Symptoms

New-onset headache is the most common cranial symptom, reported in two-thirds of patients, and is often localized to the temporal region, unilateral or bilateral, and described as aching, throbbing, or burning ^[13]^D5. Scalp tenderness and pain on combing the hair are characteristic. Jaw claudication, pain on chewing that resolves with rest, is the single strongest clinical predictor of GCA (positive likelihood ratio not calculable from reported data, but high certainty of effect in meta-analysis ^[128]^B2a). Visual symptoms occur in approximately one in six patients; transient monocular vision loss (amaurosis fugax) may precede permanent visual loss due to anterior ischemic optic neuropathy or central ^[100]^D5^[129]^D5. Constitutional symptoms, including fever, weight loss, and malaise, are present in up to 50% of patients and may dominate the picture ^[134]^D5. Limb claudication, cramping pain in the arms or legs with exercise, signals large-vessel involvement, particularly of the subclavian, axillary, or femoral arteries ^[70]^B2b. Symptoms of PMR, such as morning stiffness and pain in the shoulders, neck, and hips, co-occur in 40-60% of patients ^[56]^D5.

Neurological and Examination Findings

On examination, the temporal artery may be tender, nodular, thickened, or pulseless; a firm, beaded cord is pathognomonic but often absent ^[13]^D5. Ophthalmologic examination in patients with visual symptoms may reveal an afferent pupillary defect, optic disc edema, or pallor ^[129]^D5. Cerebrovascular events complicate about 4% of GCA cases, with two-thirds involving the vertebrobasilar territory; the presence of transient ischemic attack, large-vessel involvement, and visual manifestations each increase the risk ^[95]^B2b. Cognitive impairment has been reported in 20-43% of GCA patients, though standardized testing is rarely performed ^[127]^B2a. Blood pressure asymmetry of >10 mm Hg should raise suspicion for large-artery stenosis ^[136]^B2a.

Phenotypic Variants

GCA encompasses at least four clinical subtypes, which can be categorized by the predominant vascular territory (Table 1). Genetic profiling supports these distinctions: latent class analysis identifies cranial-predominant, mixed, extracranial, and an ischemic/occlusive high-risk subgroup ^[82]^B3b.

Table 1. Clinical Phenotypes of Giant Cell Arteritis

Variant	Key Features	Frequency at Diagnosis ^[36]^B2b	Associated Findings
Cranial	Headache, scalp tenderness, jaw claudication, visual loss	65%	High risk of permanent vision loss; temporal artery abnormalities
Extracranial (LV-GCA)	Limb claudication, aortic aneurysm/dissection, constitutional symptoms	20%	Younger age at onset, female predominance; often missed initially ^[130]^B2b
Mixed	Cranial and large-vessel features	10%	Highest burden of aortic involvement
PMR-predominant	Shoulder/hip girdle stiffness, elevated ESR/CRP, no cranial symptoms	5% (subclinical LV involvement in up to one-third ^[56]^D5)	May progress to overt GCA

Red Flags

Acute visual loss: requires immediate high-dose glucocorticoids (e.g., 1000 mg IV) to prevent permanent vision loss ^[100]^D5.
Jaw claudication: strong predictor of biopsy-positive GCA ^[128]^B2a.
Transient ischemic attack or stroke: especially vertebrobasilar; increases mortality ^[95]^B2b.
Aortic aneurysm/dissection: incidence rises 5 years after diagnosis; screening with imaging is recommended ^[70]^B2b.

Atypical Presentations

GCA may present with refractory due to aortic stiffness ^[111]^C4, isolated aortitis without cranial symptoms ^[121]^C4, or mimic ANCA-associated vasculitis when temporal arteritis reveals fibrinoid necrosis on biopsy ^[113]^B3b. The VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) should be considered in older men with treatment-refractory GCA-like symptoms, cytopenias, and characteristic bone marrow vacuoles ^[126]^C4.

Pearl: Treat any new headache in a patient >50 years with elevated ESR/CRP as GCA until proven otherwise; jaw claudication is the single strongest clinical predictor, and any acute visual loss demands immediate high-dose glucocorticoids.

Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria

▸Ultrasound is the first-line imaging test for suspected GCA; the halo sign has a sensitivity of 88% and specificity of 96%.
▸Temporal artery biopsy remains the gold standard but has a sensitivity of only ~69%; a negative biopsy does not rule out GCA.
▸The 2022 ACR/EULAR classification criteria (score ≥6) provide a validated framework for diagnosis, with ultrasound and biopsy weighted equally.

Dx Diagnostic Essentials: **Gold-standard diagnostic test:** Temporal artery biopsy remains the definitive test, but the 2023 EULAR recommendations now accept a positive halo sign on ultrasound as sufficient for diagnosis in typical clinical presentations [140].

Once the clinical suspicion is raised, the diagnostic goal is to confirm vasculitis as rapidly as possible to prevent irreversible ischaemic complications. The 2023 EULAR recommendations position ultrasound as the first-line imaging test in all patients with suspected giant cell arteritis, and the axillary arteries should be included in the standard examination ^[140]^A1c.

Imaging

Ultrasound of the temporal and axillary arteries, performed by a trained operator, reveals a non-compressible, hypoechoic, concentric wall thickening, the halo sign. In a 2023 meta-analysis of low-risk-of-bias studies, ultrasound had a pooled sensitivity of 88% (95% CI 82-92%) and specificity of 96% (95% CI 86-99%) for the diagnosis of GCA against clinical diagnosis ^[151]^A1a. When both cranial and extracranial arteries were assessed, sensitivity rose to 93% (95% CI 88-96%) with comparable specificity ^[151]^A1a. The halo sign is transient: it resolves within 2-4 weeks of starting glucocorticoids, so scanning should occur before or within days of initiating therapy ^[172]^D5. The OMERACT GCA Ultrasonography Score (OGUS) quantifies intima-media thickness across multiple segments; a higher OGUS at diagnosis is associated with an increased risk of relapse (IRR 1.85 per 1-point increase) ^[69]^B2b.

MRI (3T, high-resolution, post-contrast T1-weighted) of the scalp arteries is an alternative to ultrasound. In a prospective study of 171 patients, MRI had a sensitivity of 93.6% and a specificity of 77.9% against temporal artery biopsy ^[148]^B2b; the negative predictive value was 98.2%, suggesting that a normal MRI can reliably rule out cranial GCA.

[18F]-FDG-PET/CT is valuable when large-vessel involvement is suspected or when cranial imaging is equivocal. The GAPS study reported a sensitivity of 71% (95% CI 48-89%) and specificity of 91% (95% CI 78-97%) against clinical diagnosis, with a negative predictive value of 98% ^[158]^A1b. FDG-PET also detects incidental infections or malignancies (20% of patients in that cohort) and aortitis (42% of biopsy-positive cases) ^[158]^A1b.

Temporal Artery Biopsy (TAB)

TAB has long been the gold-standard, but it is imperfect. In the international DCVAS cohort, only 69% of patients with a clinical diagnosis of GCA had histopathologic evidence of definite vasculitis on TAB ^[124]^B2b. The classic findings, giant cells, fragmentation of the internal elastic lamina, and mononuclear infiltration, are strongly associated with the diagnosis (OR 151.8 for giant cells) but do not reliably predict clinical phenotype ^[124]^B2b. A negative TAB does not exclude GCA, especially if imaging is positive. The 2023 EULAR recommendations now allow a diagnosis of GCA without TAB when ultrasound is clearly positive ^[140]^A1c.

Laboratory Studies

Elevated acute-phase reactants are a hallmark but not diagnostic. In the 2022 ACR/EULAR criteria, ESR ≥50 mm/hour or CRP ≥10 mg/L earns +3 points ^[10]^B2b. However, up to 10% of biopsy-proven GCA patients have a normal ESR and CRP at presentation, so normal levels do not exclude the disease. ANCA testing should be performed in any patient with atypical features (e.g., renal, pulmonary, or ear-nose-throat involvement) because ANCA-associated vasculitis can mimic GCA with temporal arteritis, in one series, 88% of such patients were ANCA-positive ^[113]^B3b.

Classification Criteria: 2022 ACR/EULAR

These criteria are intended for classification in research, but they provide a useful framework for clinical diagnosis. Age ≥50 years at diagnosis is mandatory. Points are assigned as follows ^[10]^B2b:

Criterion	Points
Positive temporal artery biopsy or halo sign on ultrasound	+5
ESR ≥50 mm/hour or CRP ≥10 mg/L	+3
Sudden visual loss	+3
Morning stiffness in shoulders/neck	+2
Jaw or tongue claudication	+2
New temporal headache	+2
Scalp tenderness	+2
Temporal artery abnormality on exam	+2
Bilateral axillary involvement on imaging	+2
FDG-PET activity throughout the aorta	+2

A cumulative score of ≥6 points classifies a patient as having GCA. In the validation data set, the model had an AUC of 0.91 (95% CI 0.88-0.94), sensitivity 87.0%, and specificity 94.8% ^[10]^B2b.

Note that the halo sign on ultrasound and a positive TAB are weighted equally (+5), reflecting the shift toward imaging-based diagnosis.

Diagnostic Algorithm

A practical approach, supported by the HAS-GCA score, sequentially combines clinical probability with ultrasound ^[125]^B2b:

Calculate the Southend GCA Probability Score (SGCAPS), a validated clinical tool that incorporates age, sex, headache, jaw claudication, scalp tenderness, and ESR/CRP.
Perform ultrasound of temporal and axillary arteries. If the halo count is high, the post-test probability of GCA is very high (≥95%) and treatment can be started without biopsy.
If ultrasound is equivocal or negative but clinical suspicion remains high, proceed to TAB or MRI of the scalp arteries. FDG-PET/CT is reserved for suspected large-vessel GCA or when other modalities are unavailable.
If all tests are negative and alternative diagnoses are considered, seek a second opinion or repeat imaging after 2-4 weeks if symptoms persist.

The HAS-GCA model (SGCAPS + halo count) correctly classified 74% of patients into low- or high-probability groups with only 2% misclassification ^[125]^B2b.

Controversies and Guideline Disagreement

Question	ACR 2021 ^[141]^A1c	EULAR 2023 ^[140]^A1c	Implication
First-line diagnostic test	Temporal artery biopsy or ultrasound (conditional)	Ultrasound (strong recommendation)	EULAR prioritizes ultrasound; ACR still allows biopsy as first line
Role of biopsy	Recommended if ultrasound is negative or unavailable	Not required if ultrasound is clearly positive	Biopsy is rapidly being replaced in many centres
Screening for LV-GCA	Not specifically addressed	Include axillary arteries in standard ultrasound	Detects subclinical large-vessel disease

Pearl: In a patient with typical cranial symptoms and a positive halo sign on ultrasound, you can start high-dose glucocorticoids without waiting for a biopsy, the ultrasound has a specificity of 96% for GCA, and delaying treatment increases the risk of blindness.

Key Points

Ultrasound is the first-line imaging test for suspected GCA; the halo sign has a sensitivity of 88% and specificity of 96%.
Temporal artery biopsy remains the gold standard but has a sensitivity of only ~69%; a negative biopsy does not rule out GCA.
The 2022 ACR/EULAR classification criteria (score ≥6) provide a validated framework for diagnosis, with ultrasound and biopsy weighted equally.

Severity, Disease Activity & Risk Stratification

▸Treat-to-target in GCA aims for sustained remission and prevention of vascular damage; composite scores like OGUS and PETVAS provide prognostic information for relapse risk.
▸Higher OGUS at diagnosis (IRR 1.85 per point) and failure to normalize within 3 weeks predict future relapse; acute-phase reactants are unreliable during IL-6 blockade.
▸Damage accumulates over time (79% of patients have at least one damage item at last follow-up); large-artery complications and ocular manifestations are most common, and sustained drug-free remission is achieved in only 21% by 3-4 years.

HY High Yield: In patients treated with tocilizumab, 92% of flares occur with normal CRP levels; rely on clinical symptoms, not acute-phase reactants, to detect relapse [144].

After the diagnosis is confirmed, the next step is to stratify the patient's risk of relapse, vascular damage, and treatment-related toxicity, a process that begins by defining the current disease activity state.

Treat-to-Target and Definitions of Disease Activity

The 2024 EULAR treat-to-target (T2T) recommendations for GCA set remission as the primary treatment target, defined as the absence of clinical signs and symptoms attributable to GCA, normalization of acute-phase reactants, and no evidence of active vasculitis on imaging when performed ^[195]^A1c. Remission should be achieved and sustained while minimizing glucocorticoid exposure. Relapse (or flare) is the recurrence of GCA symptoms (with or without elevated ESR/CRP) that requires treatment intensification ^[9]^B2a^[143]^D5. Most relapses occur within the first 2 years, with approximately 50% of patients on glucocorticoid monotherapy and 30% of patients receiving experiencing a flare ^[119]^D5^[196]^A1b. The T2T framework also mandates prevention of tissue ischaemia and vascular damage, recognizing that persistent subclinical inflammation may drive long-term morbidity ^[195]^A1c.

Composite Activity Scores and Imaging Biomarkers

Validated composite scores now allow objective risk stratification. The OMERACT GCA Ultrasonography Score (OGUS) quantifies intima-media thickness (IMT) across bilateral temporal and axillary arteries, normalized to segment-specific cut-offs ^[152]^C4. In a prospective multicentre study of 97 patients, a higher OGUS at diagnosis was associated with an increased risk of relapse within 12 months (incidence rate ratio [IRR] per 1-point increase: **1.85; 95% **) ^[69]^B2b. Crucially, OGUS normalization (score <1) within the first 3 weeks was protective (IRR 0.44) and predicted longer time to first relapse ^[69]^B2b. The inter-reader intraclass correlation coefficient (ICC) among experts is 0.72-0.84, with intra-reader ICC of 0.91 ^[152]^C4^[182]^B2b.

The PET Vascular Activity Score (PETVAS), a qualitative score of global arterial FDG uptake on ¹⁸F-FDG-PET, provides complementary information. In a prospective cohort, PETVAS was independently associated with clinically active disease, and among patients in clinical remission, a high PETVAS predicted future relapse (55% vs 11%; P = 0.03) over a median follow-up of 15 months ^[202]^B2b. However, FDG-PET activity is often discordant with clinical assessment; in one RCT, baseline PET was active in only 55% of patients, and 70% of scans remained active at week 52 even in clinical remission ^[193]^A1b. A meta-analysis found that follow-up PET improved in 95% of patients who showed clinical improvement, but normalized in only 53% (78% in tocilizumab-treated patients) ^[216]^A1a. Thus, imaging should augment, not replace, clinical judgment.

Predictors of Relapse and Treatment Failure

The strongest risk factor for treatment failure in GCA is treatment with alone (OR 0.2 for tocilizumab vs placebo; P < 0.0001) ^[66]^A1b. Other independent predictors include female sex (OR 5.2 for failure with prednisone alone; 95% CI 1.6-17.2), lower baseline prednisone doses, and worse patient-reported outcomes at baseline ^[66]^A1b. In the GiACTA trial, flares occurred at a median prednisone dose of 2.0 mg/day in tocilizumab-treated patients and 5.0 mg/day in placebo-treated patients; 25% of flares in the tocilizumab group occurred while patients were taking >10 mg/day, and 92% of flares in tocilizumab-treated patients had normal CRP levels ^[144]^A1b. Therefore, acute-phase reactants are unreliable for detecting flares during IL-6 blockade ^[144]^A1b. Proteomic profiling has identified shared signatures of innate immune activation (IL-6, CCL7, CSF1) and stromal remodeling (TIMP1, TNC) that may distinguish active disease, and fibroblast activation protein alpha (FAP) is a novel candidate biomarker ^[123]^B3b^[204]^B3b.

Damage Accumulation and Prognosis

Damage is a cumulative consequence of both disease activity and treatment. In a prospective study of 204 patients with GCA, 79% had at least one damage item on the Vasculitis Damage Index (VDI) and 82% on the Large-Vessel Vasculitis Index of Damage (LVVID) at last follow-up (mean 3.5 years) ^[132]^B2b. The most common damage items were large-artery complications (29%) (stenosis, aneurysm, dissection) and ocular manifestations (22%) (especially non-ischaemic optic neuropathy) ^[132]^B2b. New damage was most frequently treatment-related: cataracts (46 patients), osteoporosis (22), and weight gain (22) ^[132]^B2b. The risk of damage increased 22% per additional year of disease duration (OR 1.22; 95% CI 1.04-1.45) ^[132]^B2b. Sustained drug-free remission (SDFR), defined as absence of active disease for ≥12 months after treatment discontinuation, was achieved in only 21.2% of 872 patients in a large Spanish registry, with cumulative rates of 6.3% at 2 years, 20.5% at 3 years, and 25.3% at 4 years ^[171]^B2b. Relapses and the need for i.v. boluses at diagnosis were negative predictors of SDFR ^[171]^B2b.

Real-world data from the French national database (18,301 incident cases) confirm that each gram of cumulative glucocorticoid exposure is associated with higher mortality (HR per gram 1.024; 95% CI 1.021-1.027), and even doses ≤5 mg/day increase the risk of serious infection and major adverse cardiovascular events ^[191]^B2b. These data underscore the imperative for rapid, effective disease control and steroid-sparing strategies, which are addressed in the following section on acute .

Pearl: The one-year risk of relapse is approximately 50% with glucocorticoid monotherapy and 30% with tocilizumab; the OGUS at diagnosis and its change over 3 weeks provides a quantifiable, early predictor of that risk, guiding the need for adjunctive therapy ^[69]^B2b^[119]^D5.

Key Composite Scores and Imaging Biomarkers for Risk Stratification in GCA

Score / Biomarker	Components	Clinical Utility	Key Thresholds	Reliability
OGUS (OMERACT GCA Ultrasonography Score)	Sum of IMT in temporal & axillary arteries, normalized by segment cut-offs and number of segments	Predicts 12-month relapse risk; early normalization (<3 weeks) is protective ^[69]^B2b^[152]^C4	Score ≥1 = active; IRR 1.85 per 1-point increase	Inter-reader ICC 0.72-0.84; intra-reader ICC 0.91 ^[152]^C4^[182]^B2b
PETVAS (PET Vascular Activity Score)	Qualitative global arterial FDG uptake on ¹⁸F-FDG-PET	Independent association with clinical activity; high PETVAS during remission predicts future relapse ^[202]^B2b	High vs low PETVAS: 55% vs 11% relapse rate at 15 months	Sensitivity 85%, specificity 83% for active LVV vs controls ^[202]^B2b
Vasculitis Damage Index (VDI) / Large-Vessel Vasculitis Index of Damage (LVVID)	Cumulative damage items (ocular, large-artery, musculoskeletal, treatment-related)	Quantifies disease- and treatment-related damage over time ^[132]^B2b	79% of patients have ≥1 VDI item; 82% have ≥1 LVVID item at 3.5 years	Not applicable (descriptive)

Acute Management: Flares & Organ-Threatening Disease

▸High-dose glucocorticoids (prednisone 40-60 mg/day or IV methylprednisolone 1 g/day for 3 days for visual loss) must be started immediately in suspected GCA flares, without waiting for confirmatory testing.
▸Tocilizumab 162 mg SC weekly is the first-line adjunctive therapy for refractory or relapsing flares; upadacitinib 15 mg daily and secukinumab 300 mg weekly are newer alternatives supported by phase 2/3 trials.
▸Do not use antiplatelet or anticoagulant therapy for the vasculitis itself; clinical assessment is the primary guide to disease activity in tocilizumab-treated patients because CRP becomes unreliable.

Rx Drug of Choice: For acute organ-threatening GCA (visual loss, TIA, stroke): **IV methylprednisolone 1 g/day for 3 days** followed by oral prednisone 40-60 mg/day. For refractory/relapsing disease: **tocilizumab 162 mg SC weekly** plus a 26-week glucocorticoid taper [196, 219].

! Warning: **Do not delay glucocorticoid therapy for temporal artery biopsy or imaging.** A 1-2 week window of treatment does not compromise pathology [27]. Delaying treatment risks irreversible blindness.

The risk stratification completed in the preceding section directly informs the urgency of intervention: patients with cranial ischemic symptoms, particularly visual loss or amaurosis fugax, require immediate high-dose glucocorticoid therapy without waiting for biopsy or imaging results ^[219]^A1c (1c). Delay of even a few hours can convert reversible ischemia into permanent infarction ^[100]^D5 (5).

Step 1: Initial Assessment and Severity Classification

Distinguish a simple flare (recurrence of headache, jaw claudication, PMR symptoms, or rise in inflammatory markers) from organ-threatening disease (acute visual loss, transient ischemic attack, stroke, aortic dissection, or large-artery stenosis). Any patient with sudden vision loss, diplopia, or transient monocular visual loss has an ophthalmologic emergency and should be evaluated immediately. The 2021 ACR/Vasculitis Foundation guideline recommends that glucocorticoids be started at the earliest suspicion of active GCA, especially when cranial ischemic symptoms are present ^[219]^A1c (1c).

Step 2: First-Line Intervention for Acute Flare and Organ-Threatening Disease

Administer high-dose glucocorticoids immediately. For patients without visual loss or other organ-threatening features, start 40-60 mg/day orally or IV equivalent ^[192]^A1c (1c). For patients with acute visual loss or amaurosis fugax, give IV 1 g/day for 3 days, followed by a high-dose oral taper ^[34]^B2b^[219]^A1c (2b, 1c). The 2021 ACR guideline makes a conditional recommendation for IV methylprednisolone in this setting ^[219]^A1c (1c). A multicenter inception cohort study (N=206) found that methylprednisolone pulses were associated with faster remission (average treatment effect -14.2 weeks; 95% CI -20.5 to -7.8) and a lower cumulative prednisone dose at 3 months (733 mg vs 1902 mg; P<0.001) ^[34]^B2b (2b).

Do not delay therapy for diagnostic tests. Temporal artery biopsy or imaging can be performed within 1-2 weeks of starting glucocorticoids without loss of diagnostic sensitivity ^[27]^A1a (1a).

Do not initiate antiplatelet or anticoagulant therapy for the vasculitis itself; the EULAR 2018 recommendation advises against routine use unless indicated for comorbid conditions ^[192]^A1c (1c).

Step 3: Second-Line Interventions for Refractory or Relapsing Flares

If the patient does not respond to glucocorticoids within 1-2 weeks, or if a flare occurs during glucocorticoid taper, add a glucocorticoid-sparing agent. The 2021 ACR guideline conditionally recommends adjunctive therapy in patients with refractory or relapsing disease, or at high risk for glucocorticoid toxicity ^[219]^A1c (1c).

Drug	Dose	Key trial	Outcome	Evidence level
	162 mg SC weekly (or 8 mg/kg IV monthly)	GiACTA (N=251)	Sustained glucocorticoid-free remission at week 52: 56% (weekly) vs 14% (placebo+26-week taper) ^[196]^A1b	1b
Upadacitinib	15 mg PO daily	SELECT-GCA (N=428)	Sustained remission at week 52: 46.4% vs 29.0% (placebo+52-week taper); P=0.002 ^[147]^A1b	1b
Secukinumab	300 mg SC weekly ×4 then Q4W	TitAIN (N=52)	Sustained remission to week 28: 70% vs 20% (placebo) ^[68]^A1b	1b
Mavrilimumab	150 mg SC Q2W	Phase 2 (N=70)	Flare by week 26: 19% vs 46% (placebo); HR 0.38 ^[220]^A1b	1b
Baricitinib	4 mg PO daily	Open-label pilot (N=15)	93% achieved glucocorticoid-free remission at week 52 ^[153]^C4	4
	15-25 mg PO/SC weekly	Meta-analysis	Modest glucocorticoid-sparing effect; less effective than tocilizumab ^[192]^A1c^[219]^A1c	1a

Step 4: Monitoring and Titration

Monitor clinical response daily during the acute phase: resolution of headache, jaw claudication, visual symptoms, and PMR symptoms. Inflammatory markers (CRP, ESR) are helpful but become discordant in patients receiving tocilizumab, which normalizes CRP rapidly regardless of disease activity ^[144]^A1b (1b). The key is clinical assessment.

Begin glucocorticoid taper once the flare is controlled. The ACR 2021 guideline recommends a taper over 6-12 months, but a 26-week taper is feasible when a steroid-sparing agent is used ^[196]^A1b^[219]^A1c (1b, 1c). Monitor for glucocorticoid adverse effects: blood glucose, blood pressure, bone density, and infection risk.

Step 5: Resolution and Transition to Long-Term

Once the patient is stable on a low-dose glucocorticoid or off glucocorticoids, transition to the long-term management algorithm described in the next section. For patients on tocilizumab, continue for at least 12 months; after discontinuation, approximately 50% will relapse within 1-2 years ^[207]^B2b (2b).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication for practice
Routine use of IV methylprednisolone for acute GCA without visual loss	ACR 2021, conditional recommendation for IV pulses only in acute visual loss ^[219]^A1c	EULAR 2018, does not specifically recommend IV pulses; high-dose oral is sufficient ^[192]^A1c	Moderate	Clinicians may reserve IV pulses for visual loss; observational data suggest broader benefit may exist ^[34]^B2b
Antiplatelet therapy in GCA	EULAR 2018, recommends against routine use ^[192]^A1c	ACR 2021, no recommendation for or against	Mild	Do not prescribe or anticoagulants for GCA alone; use only for established cardiovascular indications

Pearl: In acute visual loss from GCA, start IV methylprednisolone 1 g/day immediately, do not wait for biopsy or imaging results; every hour of delay increases the risk of irreversible blindness ^[100]^D5^[219]^A1c.

Long-term Management: The DMARD Ladder & Treat-to-Target

▸Tocilizumab 162 mg weekly plus a 26-week prednisone taper is the most effective biologic for sustained remission (NNT 2.4) and reduces HbA1c independent of glucocorticoid dose.
▸Methotrexate is recommended as first-line in all patients without ischaemic symptoms by the Turkish Society, but toxicity risk is elevated in elderly patients on diuretics or PPIs.
▸Upadacitinib 15 mg daily is a new second-line option for patients with low cardiovascular risk, with sustained remission of 46.4% vs 29.0% (NNT 5.7).
▸Treat-to-target targets: remission, prevention of tissue ischaemia, and avoidance of vascular damage; acute-phase reactants are unreliable for monitoring during tocilizumab therapy.

Rx Drug of Choice: Tocilizumab 162 mg subcutaneously weekly is the first-line biologic for glucocorticoid-sparing therapy in GCA, yielding sustained remission in 56% at 52 weeks (GiACTA).

! Warning: Methotrexate toxicity is life-threatening in elderly patients with impaired renal function, especially those on diuretics or proton pump inhibitors, monitor eGFR and folinate rescue if toxicity suspected [102].

Once acute threats are controlled, the central challenge shifts to maintaining remission while minimizing cumulative glucocorticoid exposure. The 2024 EULAR treat-to-target recommendations for GCA define the treatment targets as achievement and maintenance of remission, prevention of tissue ischaemia, and avoidance of vascular damage ^[195]^A1c. should be guided by shared decision-making, acknowledging that even low-dose glucocorticoids carry dose-dependent risks: each additional gram of cumulative increases mortality (HR 1.024 per gram, 95% CI 1.021-1.027) ^[191]^B2b. This mandates a structured DMARD ladder.

Step 1: Identify Candidates for a Glucocorticoid-Sparing Agent

Not every patient requires a DMARD. The 2018 EULAR recommendations advise adjunctive therapy in patients with refractory or relapsing disease, or those at increased risk for glucocorticoid-related adverse events ^[192]^A1c. The French GEFA 2024 guideline specifies that patients with a prior major cardiovascular event, osteoporosis with fracture, psychiatric event on glucocorticoids, complicated diabetes, or any prior >6 months of glucocorticoid therapy should receive at diagnosis with a 6-month glucocorticoid taper ^[261]^D5. The Turkish Society for Rheumatology 2026 recommendations go further, recommending in addition to glucocorticoids as first-line in all patients without ischaemic symptoms ^[169]^A1c.

Step 2: First-Line DMARD, Methotrexate or Tocilizumab?

Methotrexate (MTX) is the most prescribed conventional synthetic DMARD. In French real-world data, 12% of GCA patients received MTX ^[256]^B2b. The 2022 GiACTA long-term extension showed that MTX use was associated with a lower cumulative glucocorticoid dose (median 4418 mg vs 5637 mg with prednisolone alone) and a higher probability of glucocorticoid discontinuation (RR 6.77, 95% CI 1.01-45.29) ^[257]^B2b. However, MTX toxicity is a concern in the elderly: patients >70 years on diuretics or proton pump inhibitors have a significantly higher risk of severe toxicity ^[102]^B3b.

Tocilizumab (TCZ) is the only biologic approved for GCA. In the GiACTA trial, subcutaneous TCZ 162 mg weekly plus a 26-week prednisone taper yielded sustained glucocorticoid-free remission at week 52 in 56% of patients, compared with 14% in the placebo-plus-26-week-taper group (P<0.001; NNT = 2.4) ^[196]^A1b. TCZ every other week was also superior (53% vs 14%). The 3-year extension data showed that 42% of patients initially randomised to TCZ weekly maintained remission without any treatment through part 2 ^[207]^B2b. TCZ also improves glycaemic control: median HbA1c decreased by 0.50% in the TCZ/glucocorticoid group vs 0.10% in the glucocorticoid-only group, and 42.5% of patients with reverted to normoglycaemia ^[1]^A1b.

Choice between MTX and TCZ: The Turkish Society recommends MTX first-line for all without ischaemic symptoms; the French GEFA recommends TCZ first when a glucocorticoid-sparing agent is needed, especially in patients with high risk of glucocorticoid toxicity. In practice, TCZ is preferred in patients with ischaemic complications, those who cannot tolerate MTX, or those with a high risk of glucocorticoid-related adverse events.

Step 3: Second-Line and Refractory Disease

For patients who fail or are intolerant to first-line therapy, several options exist:

Abatacept (10 mg/kg IV on days 1, 15, 29 and week 8, then monthly) prolonged remission compared with placebo (median duration 9.9 months vs 3.9 months; P=0.023) ^[194]^A1b.
Upadacitinib 15 mg once daily plus a 26-week glucocorticoid taper was superior to placebo with a 52-week taper for sustained remission at week 52 (46.4% vs 29.0%; P=0.002; NNT = 5.7) ^[147]^A1b. The 7.5 mg dose was not superior. The Turkish Society recommends upadacitinib as an alternative to TCZ in patients with low cardiovascular risk ^[169]^A1c.
Mavrilimumab (150 mg subcutaneously every 2 weeks) reduced the hazard of flare by 62% vs placebo (HR 0.38, 95% CI 0.15-0.92) and achieved sustained remission at week 26 in 83% vs 50% (P=0.0038; NNT = 3.0) ^[220]^A1b.
Secukinumab 300 mg did not meet its primary endpoint in the phase 3 GCAptAIN trial (sustained remission 25.6% vs 16.9%; P=0.09) ^[168]^A1b.
Anakinra and guselkumab have shown no benefit in randomised trials ^[248]^A1b^[142]^A1b.

Step 4: Duration of Therapy and Tapering

TCZ is typically administered for at least 12 months. In the GiACTA long-term extension, patients who stopped TCZ at or before 12 months had a higher relapse risk than those who continued beyond 12 months (adjusted HR 0.01, 95% CI 0.00-0.28; P=0.005) ^[184]^B2b. In a multicentre service evaluation, 48.6% of patients relapsed by 24 months after stopping TCZ, with a median prednisolone increase to 20 mg/day ^[254]^B2b. The 2024 French GEFA recommends continued TCZ for at least 12 months, with a goal of discontinuing glucocorticoids within 6 months ^[261]^D5.

Step 5: Monitoring and Treat-to-Target

At each visit, assess for clinical signs of relapse, measure acute-phase reactants (CRP, ESR), and monitor glucocorticoid dose. The 2024 T2T recommendations stress that acute-phase reactants are unreliable in patients on TCZ, as 92% of flares in TCZ-treated patients occurred with normal CRP levels ^[144]^A1b^[195]^A1c. Imaging (PET/CT, MRA) may show persistent vessel wall enhancement even in clinical remission, but its role in guiding treatment decisions remains unclear ^[241]^A1b^[224]^B2b.

Drug / Modality Comparison Table

Option	Indication / Line	Dose or Specifics	Key Trial	Outcome	NNT
Tocilizumab	First-line (selected) or second-line	162 mg SC weekly + 26-wk prednisone taper	GiACTA ^[196]^A1b	Sustained remission at 52 wk: 56% vs 14%	2.4
Methotrexate	First-line (Turkish Society) or second-line	15-25 mg PO/SC weekly	RIGA ^[257]^B2b	Lower cumulative GC dose (4418 vs 5637 mg)	Not calculable
Upadacitinib	Second-line (low CV risk)	15 mg PO daily + 26-wk GC taper	SELECT-GCA ^[147]^A1b	Sustained remission at 52 wk: 46.4% vs 29.0%	5.7
Abatacept	Second-line	10 mg/kg IV days 1,15,29, then monthly	Langford 2017 ^[194]^A1b	Median remission duration 9.9 vs 3.9 mo	6.0
Mavrilimumab	Investigational second-line	150 mg SC q2w + 26-wk GC taper	Cid 2022 ^[220]^A1b	Sustained remission at 26 wk: 83% vs 50%	3.0

What NOT to Do

Do not use anti-TNF agents ( , , ), they have shown no benefit in GCA ^[237]^A1b^[238]^A1b^[242]^A1b.
Do not routinely use antiplatelet or anticoagulant therapy for GCA itself unless indicated for other reasons ^[192]^A1c.
Do not rely on CRP/ESR alone to guide therapy in TCZ-treated patients ^[144]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line DMARD for all patients without ischaemic symptoms	Turkish Society 2026, recommend MTX as first-line ^[169]^A1c	EULAR 2018, suggest adjunctive therapy only in selected patients (refractory/relapsing/high risk) ^[192]^A1c	Moderate	Turkish practice uses MTX more broadly; European practice reserves TCZ for higher-risk patients
Role of upadacitinib as alternative to TCZ	Turkish Society 2026, recommend upadacitinib as alternative in low CV risk ^[169]^A1c	EULAR 2018, no mention of upadacitinib; TCZ is the only recommended biologic ^[192]^A1c	Moderate	Upadacitinib is an emerging option, but CV risk in elderly GCA population warrants caution

Pearl: In patients with GCA requiring a glucocorticoid-sparing agent, tocilizumab 162 mg weekly with a 26-week prednisone taper achieves sustained remission in 56% (NNT 2.4) and reduces HbA1c independently of glucocorticoid exposure; methotrexate is a reasonable alternative first-line in patients without ischaemic symptoms, but monitor for toxicity in elderly patients on diuretics or PPIs ^[102]^B3b^[196]^A1b^[1]^A1b.

DMARD Dosing Table

Drug	Starting dose	Target / max dose	Renal adjustment	Hepatic adjustment	Key monitoring
Tocilizumab	162 mg SC weekly	162 mg weekly	None	None	Neutrophil count, platelets, LFTs, infections
Methotrexate	10-15 mg PO/SC weekly	25 mg weekly	eGFR <30: avoid	Avoid in significant liver disease	CBC, LFTs, creatinine, folate
Upadacitinib	15 mg PO daily	15 mg daily	Avoid if eGFR <30	Child-Pugh B/C: avoid	Neutrophils, lymphocytes, Hb, LFTs, lipids
Abatacept	10 mg/kg IV days 1,15,29, then monthly	10 mg/kg monthly	None	None	Infections
Mavrilimumab (investigational)	150 mg SC q2w	150 mg q2w	Not established	Not established	Infections, neutropenia

Immunosuppression Safety & Therapeutic Drug Monitoring

▸Pre-biologic screening for latent TB, hepatitis B/C, and HIV is mandatory before starting IL-6 inhibitors [43].
▸Monitor neutrophil count, liver enzymes, and lipids every 4-8 weeks for the first 6 months of tocilizumab therapy [43,184].
▸Serious infections occur at ~10-13 per 100 patient-years; no routine PJP prophylaxis is needed unless concurrent high-dose glucocorticoids [265,266].

! Warning: Serious infections (rate 10.6/100 patient-years) are the most common adverse event with tocilizumab; risk is highest in the first 3 months and with prednisone >15 mg/day [266].

Once a biologic is selected, a structured safety surveillance program becomes the backbone of ongoing care, mitigating the toxicity risks that accompany long-term immunosuppression. The treat-to-target approach demands parallel vigilance for drug toxicity, particularly with interleukin-6 (IL-6) pathway inhibitors, the only biologic class approved for GCA.

Pre-Biologic Screening

Before initiating or , screen for latent tuberculosis (interferon-gamma release assay), hepatitis B, hepatitis C, and HIV ^[43]^A1c. Obtain baseline , liver enzymes, and lipid panel. For IL-6 inhibitors, elevated transaminases and neutropenia are known class effects; baseline values guide subsequent monitoring. In a real-world cohort of 134 patients, 73.1% had received prior immunosuppressants, and serious infections occurred at a rate of 10.6 per 100 patient-years ^[266]^C4.

Ongoing Lab Monitoring

During treatment, monitor neutrophil count, platelet count, and ALT/AST every 4-8 weeks for the first 6 months, then every 2-3 months ^[43]^A1c^[184]^B2b. For tocilizumab, grade 3 or higher LFT elevation occurs in 2-3% of patients; neutropenia (absolute neutrophil count <1000/μL) may require dose interruption or reduction ^[184]^B2b. Lipid profile should be checked 4-8 weeks after starting therapy, then every 6-12 months, as IL-6 inhibitors raise total cholesterol and triglycerides ^[43]^A1c. The table below summarizes the recommended schedule.

Parameter	Baseline	Frequency (first 6 months)	Chronic frequency	Action if abnormal
CBC with differential	✓	Every 4-8 weeks	Every 2-3 months	Hold if ANC <1000/μL ^[184]^B2b
ALT/AST	✓	Every 4-8 weeks	Every 2-3 months	Hold if >3× ULN; resume when <2× ULN ^[43]^A1c
Lipid panel	✓	At 4-8 weeks	Every 6-12 months	Start statin per guidelines ^[43]^A1c
Infection screen (TB, HBV, HCV, HIV)	✓	,	,	Treat latent TB before starting ^[43]^A1c

Infection Prophylaxis

Serious infections are the most common safety concern. In the aortitis cohort, the serious adverse event rate was 8.7 per 100 patient-years with TCZ combined with csDMARDs and 13.2 per 100 patient-years with TCZ monotherapy (p=0.21) ^[265]^B2b. No routine prophylaxis is recommended for GCA biologics alone, but consider it in patients receiving high-dose glucocorticoids (>20 mg daily for >4 weeks) or with additional risk factors ^[43]^A1c. Influenza and pneumococcal vaccines should be given before starting biologic therapy ^[43]^A1c.

Perioperative

For elective surgery, hold tocilizumab for 4 weeks before the procedure (or one dosing interval), and resume after adequate wound healing, typically 2 weeks post-surgery provided no infection ^[43]^A1c. For secukinumab, hold for 4 weeks prior. If the patient is adrenally suppressed from glucocorticoid therapy, administer stress-dose corticosteroids perioperatively.

Therapeutic Drug Monitoring

Routine therapeutic drug monitoring (TDM) for tocilizumab or secukinumab is not established in GCA. No target concentration has been validated. Dosing is fixed: tocilizumab 162 mg subcutaneously weekly, secukinumab 300 mg subcutaneously weekly for 4 weeks then every 4 weeks ^[68]^A1b^[184]^B2b. Drug levels may be considered in cases of suspected loss of efficacy or paradoxical reactions, but evidence is lacking ^[43]^A1c.

Pearl: Serious infection risk is highest during the first 3 months of tocilizumab therapy, especially when the prednisone dose exceeds 15 mg/day, withhold the biologic if infection develops and restart once adequately treated.

Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)

▸Vision loss occurs in ~1 in 6 patients; orbital MRI with retrobulbar fat enhancement reliably distinguishes arteritic from non-arteritic AION.
▸Cerebrovascular accidents occur in ~4% of patients, predominantly vertebrobasilar, and are associated with TIA, large-vessel involvement, and visual symptoms.
▸Large-vessel stenotic disease affects <10% of patients but carries a 19.5% cumulative incidence of vascular complications at 10 years; thoracic aortic aneurysm risk is 13-fold higher than the general population.
▸Clonal haematopoiesis (TET2 mutations) and VEXAS syndrome (UBA1 mutations) are emerging mimics and modifiers of GCA that should be considered in atypical presentations.

HY High Yield: When a patient with suspected GCA presents with atypical features (renal, pulmonary, neurologic, or ear-nose-throat involvement), check ANCA serology and consider temporal artery biopsy for fibrinoid necrosis or small-branch vasculitis, which point to ANCA-associated vasculitis rather than classic GCA [113].

! Warning: The risk of serious infection is highest in the first 6 months after GCA diagnosis, especially with glucocorticoid doses ≥10 mg/day prednisone equivalent. Infections are a leading cause of morbidity; pneumococcal and influenza vaccination should be prioritised at diagnosis [76,78].

Building on the need to minimise glucocorticoid toxicity, a clear understanding of which organ systems GCA targets is essential for focused screening and monitoring. The disease is not limited to cranial arteries; it produces a spectrum of vascular and systemic manifestations that vary by territory and often run a subclinical course.

Cranial and Ocular Involvement

The most feared complication is permanent vision loss, occurring in approximately one in six patients ^[100]^D5. Vision loss typically results from arteritic anterior ischaemic optic neuropathy (A-AION) due to inflammation of the ophthalmic artery branches. Orbital MRI can help differentiate A-AION from non-arteritic AION: retrobulbar fat enhancement on MRI achieves 100% sensitivity (95% CI 72-100) and 89% specificity for A-AION ^[181]^B2b. Even without visual symptoms, optical coherence tomography angiography (OCTA) reveals reduced vessel density in the superficial peripapillary plexus, suggesting early retinal hypoperfusion ^[185]^B3b.

Cerebrovascular accidents (CVA) occur in 3.96% of patients, predominantly in the vertebrobasilar territory (62.3%) ^[95]^B2b. Factors independently associated with CVA include transient ischaemic attack (OR 8.63), large-vessel involvement (OR 2.79), and concurrent visual manifestations (OR 2.73). Mortality is doubled in patients with CVA (18% vs 8.8%, P=0.014) ^[95]^B2b.

Large-Vessel Involvement

Large-vessel giant cell arteritis (LV-GCA) affects the aorta and its branches in up to 70% of patients, often without cranial symptoms ^[162]^D5. Stenotic LV-GCA is less common (6.3% of GCA patients) but carries a poor prognosis: the subclavian (63%), carotid (58%), vertebral (37%), and axillary (33%) arteries are most frequently involved ^[84]^B2b. The cumulative incidence of vascular complications (stroke, limb ischaemia, myocardial infarction, mesenteric ischaemia) is 13.1% at 1 year, 17.3% at 5 years, and 19.5% at 10 years ^[84]^B2b. Age at diagnosis (HR 1.06 per year, 95% CI 1.03-1.10) and vertebral artery involvement (HR 1.87) independently predict complications ^[84]^B2b.

Aortic involvement manifests as wall thickening, stenosis, or dilatation. The incidence of large-artery involvement has increased over time, with a 15-year cumulative incidence rising from 14.8% (1950-1974) to 49.2% (2000-2016) (HR 3.48, 95% CI 1.67-7.27) ^[105]^B2b. Compared with the general population, GCA patients have a markedly higher risk of (HR 13.46, 95% CI 1.78-101.98) but not abdominal aneurysm ^[105]^B2b. Subclavian artery dilatation, a distinct subset, is strongly associated with aortic aneurysm: 64% of patients with subclavian dilatation developed aortic aneurysm at 5 years versus 7% of those with stenotic LV-GCA ^[90]^B2b.

Cardiovascular and Cerebrovascular

Myocardial infarction is a recognised complication of stenotic LV-GCA, occurring in 4% of affected patients ^[84]^B2b. Refractory can be the presenting feature of GCA, as illustrated by case reports of new-onset hypertension with headache and elevated inflammatory markers that resolved with glucocorticoid therapy ^[111]^C4.

Other Organ Systems

: Mesenteric artery involvement occurs in 13% of stenotic LV-GCA patients, leading to mesenteric ischaemia in 2% ^[84]^B2b. GCA can co-occur with inflammatory bowel disease (IBD): in a case-control study, GCA-IBD patients had more frequent arterial thickening or stenosis (75% vs 30%) and a trend toward more gastrointestinal artery involvement (20% vs 0%) ^[273]^B3b.

Renal and Pulmonary: Although rare, ANCA-associated vasculitis can present with temporal arteritis, mimicking GCA. In one series, 66% of such patients had atypical symptoms including ear-nose-throat (32%), renal (26%), pulmonary (20%), and neurologic (16%) involvement ^[113]^B3b. ANCA serology should be checked when atypical features are present or when biopsy shows fibrinoid necrosis or small-branch vasculitis ^[113]^B3b.

Cutaneous and Haematologic: VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) caused by somatic UBA1 mutations can present with GCA-like cranial symptoms; in one cohort, 23.6% of VEXAS patients had vasculitis, predominantly cutaneous small-vessel disease ^[94]^C4^[126]^C4. Clonal haematopoiesis, particularly TET2 mutations, increases the risk of both GCA (HR 2.02) and GCA-associated vision loss (OR 4.33) ^[118]^B2b.

Infectious Risk: Patients with GCA have a 48% increased rate of lower respiratory tract infections and 55% increased rate of serious infections, with the highest risk in the first 6 months after diagnosis ^[76]^B2b. During the pandemic, glucocorticoid doses ≥10 mg/day were associated with a 2.14-fold higher odds of poor COVID-19 outcomes ^[78]^B2b.

Pearl: A patient with GCA and new-onset headache, refractory hypertension, or unexplained stroke, especially in the vertebrobasilar territory, should prompt urgent evaluation for large-vessel stenotic disease, as these complications carry a doubled mortality risk.

Organ-System Involvement in Giant Cell Arteritis

Organ System	Manifestation	Frequency / Key Finding	Reference
Cranial/Ocular	Arteritic AION (vision loss)	~1 in 6 patients	^[100]^D5
	Retinal microvascular changes on OCTA	Reduced superficial plexus density, even without visual symptoms	^[185]^B3b
Cerebrovascular	Stroke (mainly vertebrobasilar)	3.96% of patients; mortality 18% vs 8.8%	^[95]^B2b
Large Vessel	Stenotic LV-GCA (subclavian, carotid, vertebral, axillary)	6.3% of GCA; cumulative vascular complications 13.1% at 1 yr, 19.5% at 10 yr	^[84]^B2b
	Thoracic aortic aneurysm	HR 13.46 vs general population	^[105]^B2b
	Subclavian dilatation → aortic aneurysm	64% at 5 yr	^[90]^B2b
Cardiovascular	Myocardial infarction	4% of stenotic LV-GCA patients	^[84]^B2b
	Refractory hypertension	Case reports, resolves with glucocorticoids	^[111]^C4
Gastrointestinal	Mesenteric artery stenosis/ischaemia	13% stenosis, 2% ischaemia in stenotic LV-GCA	^[84]^B2b
	Co-occurrence with IBD	More arterial thickening/stenosis (75% vs 30%)	^[273]^B3b
Renal/Pulmonary	ANCA-associated vasculitis mimicking GCA	26% renal, 20% pulmonary involvement in TA-AAV	^[113]^B3b
Haematologic	Clonal haematopoiesis (TET2)	OR 2.02 for GCA, OR 4.33 for vision loss	^[118]^B2b
	VEXAS syndrome (UBA1)	23.6% with vasculitis, can mimic GCA	^[94]^C4^[126]^C4
Infectious	LRTI, UTI, serious infections	48% increased LRTI, 55% increased serious infections; highest in first 6 months	^[76]^B2b
	COVID-19 poor outcome	OR 2.14 with prednisone ≥10 mg/day	^[78]^B2b

Complications: Disease-Driven & Treatment-Related

▸Disease-driven complications include aortic aneurysm (2-fold risk, 4.5-fold faster growth), ocular damage (22%), and large-artery stenosis/occlusion (29%).
▸Treatment-related damage dominates: severe infections (11.1/100 pt-yrs in year 1), osteoporosis, diabetes, and cataracts are the most common new damage items.
▸Each gram of cumulative glucocorticoid increases mortality (HR 1.024/g); even doses ≤5 mg/day carry elevated infection and MACE risk.

! Warning: Severe infections are the leading cause of readmission (23%) and peak in the first year after diagnosis. Pneumocystis jirovecii pneumonia, though rare, carries 29% mortality and is preventable with prophylaxis [6,71,75].

HY High Yield: Aortic aneurysm growth is 4.5-fold faster in GCA-associated aortitis than degenerative aneurysms; consider annual surveillance imaging in patients with large-vessel involvement [294,288].

Having surveyed the organ-by-organ map of GCA, the clinician must now weigh two competing sources of long-term morbidity: damage from the vasculitis itself and iatrogenic harm from chronic immunosuppression. Both dominate outcomes and require distinct preventive strategies.

Disease-Driven Complications

Aortic aneurysm is the most feared late vascular complication. Patients with GCA have a twofold increased risk of aortic aneurysm compared with age- and sex-matched controls (adjusted subhazard ratio 1.92, 95% CI 1.52-2.41) ^[288]^B3b. Among those with histologically proven aortitis, preoperative thoracic aneurysm growth is 4.5-fold faster than degenerative aneurysms (0.177 vs 0.039 mm/month; p<0.001), with clinically isolated aortitis growing even faster than GCA-associated aortitis ^[294]^B3b. Large-artery complications (stenosis, occlusion, aneurysm) are the most frequently recorded damage items, occurring in 29% of patients in a prospective longitudinal cohort ^[132]^B2b. Ocular damage, chiefly ischaemic optic neuropathy, affects 22% of patients and remains the most common new damage item during follow-up ^[132]^B2b. Although permanent vision loss is now less frequent than in the pre-glucocorticoid era, it still occurs in approximately one in six patients and is typically irreversible ^[100]^D5. Stroke and myocardial infarction rates are not significantly elevated over the general population after adjustment for cardiovascular risk factors ^[73]^B2b, but relapse independently predicts future cardiovascular events (OR 5.01, 95% CI 1.55-16.22) ^[104]^B2b.

Treatment-Related Complications

Glucocorticoid toxicity accounts for the majority of new damage. In the Vasculitis Damage Index, treatment-associated items, cataracts (46 patients), osteoporosis (22), weight gain (22), outnumber disease-driven items ^[132]^B2b. The risk of damage increases 22% for every additional year of disease duration (OR 1.22, 95% CI 1.04-1.45) ^[132]^B2b. Severe infections are the leading cause of readmission (23% of 6-month readmissions) and are concentrated in the first year after diagnosis, with an incidence rate of 11.1 per 100 patient-years (incidence rate ratio 2.1 vs controls) ^[71]^B2b^[75]^B2b. Each gram of cumulative glucocorticoid exposure is associated with higher mortality (HR 1.024 per gram, 95% CI 1.021-1.027), and even doses ≤5 mg/day carry increased infection and MACE risk ^[191]^B2b. Diabetes, , and osteoporosis are strongly associated with GCA in population-based studies (RR 2.9 for osteoporosis, RR 2.6 for ) ^[19]^B3b. Pneumocystis jirovecii pneumonia, though rare, carries a 29% mortality in GCA patients and is preventable with prophylaxis ^[6]^C4.

Complication	Disease-Driven	Treatment-Related	Key Evidence
Aortic aneurysm	2-fold risk; 4.5-fold faster growth	,	^[288]^B3b^[294]^B3b
Ocular damage	22% of patients; ischaemic optic neuropathy	Cataracts (46 patients)	^[132]^B2b^[100]^D5
Large-artery stenosis/occlusion	29% of patients	,	^[132]^B2b
Severe infection	,	11.1/100 pt-yrs in year 1; 23% of readmissions	^[71]^B2b^[75]^B2b
Osteoporosis	,	RR 2.9; 22 patients with new damage	^[132]^B2b^[19]^B3b
Diabetes	,	RR 2.9; 11% in rapid-taper cohort	^[19]^B3b^[223]^B3b
Cardiovascular events	Relapse predicts events (OR 5.01)	MACE risk even at ≤5 mg/day GC	^[104]^B2b^[191]^B2b
Malignancy	No increased risk (SIR 1.2, 95% CI 0.8-1.6)	,	^[74]^B2b^[292]^B3b

Prevention and Monitoring

Given the predominance of treatment-related damage, the central goal of long-term is glucocorticoid minimization. Steroid-sparing agents, particularly and , reduce cumulative exposure and associated toxicity ^[214]^A1a^[169]^A1c. The 2024 German S2e guidelines recommend adding an IL-6 receptor blocker (or alternatively methotrexate) in relapsing disease and considering it in new-onset patients at high risk for glucocorticoid adverse events ^[236]^A1c. Upadacitinib 15 mg daily with a 26-week taper is a newer option for patients with low cardiovascular risk ^[147]^A1b^[169]^A1c. Routine screening for osteoporosis (DXA), diabetes (fasting glucose), and hypertension should accompany every visit ^[178]^D5. Annual surveillance imaging for aortic aneurysm is not universally recommended but should be considered in patients with large-vessel involvement or persistent inflammation ^[288]^B3b^[174]^D5.

Pearl: Treatment-related damage, especially infection, osteoporosis, and cataracts, outweighs disease-driven complications in GCA; every effort to minimize cumulative glucocorticoid exposure through early use of steroid-sparing agents (tocilizumab, methotrexate, upadacitinib) directly reduces long-term morbidity and mortality ^[191]^B2b^[132]^B2b^[214]^A1a.

History and Evolution of Treatment

▸Glucocorticoids remain first-line but tocilizumab has revolutionized steroid-sparing therapy with phase 3 evidence of 56% sustained remission at 52 weeks.
▸Multiple biologic pathways have been tested; only IL‑6 blockade (tocilizumab) and JAK inhibition (upadacitinib) have shown consistent efficacy in phase 3 trials.
▸TNF inhibitors, IL‑1 blockade, and IL‑23 blockade have all failed to demonstrate benefit in randomized controlled trials.

The complications of long-term glucocorticoid exposure, infections, fractures, diabetes, have driven a decades-long search for steroid-sparing therapies that has reshaped the treatment landscape. High-dose glucocorticoids (40-60 mg/day -equivalent) remain the urgent foundation for inducing remission, but their toxicity profile has motivated systematic evaluation of alternative and adjunctive agents ^[192]^A1c.

The Glucocorticoid Era

For decades, GCA was managed exclusively with glucocorticoids, tapered over 12-24 months. A 1996 randomized trial of 7.5 mg/week found no steroid-sparing effect compared with placebo ^[295]^A1b. Subsequent larger studies confirmed only a modest benefit, and methotrexate is now considered a second-line option ^[192]^A1c.

Failed Biologic Pathways

Three anti-TNF agents were tested in randomized controlled trials, all with negative results. 40 mg every other week for 10 weeks added to prednisone did not increase the proportion of patients in remission on <0.1 mg/kg prednisone at 26 weeks (58.9% vs 50.0%, P = 0.46) ^[237]^A1b. showed no significant difference in corticosteroid withdrawal at 12 months in a small trial of 17 patients ^[238]^A1b. was similarly ineffective. Anakinra (IL-1 blockade) 100 mg daily for 16 weeks did not reduce relapse rates or glucocorticoid exposure at week 52 ^[248]^A1b. Guselkumab (IL-23p19 inhibitor) failed to meet its primary endpoint of glucocorticoid-free remission at week 28 (40% vs 33%, P = 0.64) ^[142]^A1b.

The Revolution

The most transformative advance came with IL-6 receptor blockade. The phase 2 trial by Villiger et al. showed that tocilizumab 8 mg/kg IV every 4 weeks plus prednisone achieved complete remission at week 12 in 85% of patients versus 40% in the placebo group ^[146]^A1b. The landmark GiACTA phase 3 trial randomized 251 patients to subcutaneous tocilizumab 162 mg weekly or every‑other‑week with a 26‑week prednisone taper, versus placebo with a 26‑ or 52‑week taper. Sustained remission at week 52 occurred in 56% (weekly) and 53% (every‑other‑week) versus 14% and 18% in the placebo groups (P<0.001) ^[196]^A1b. Cumulative median prednisone dose over 52 weeks was 1862 mg in each tocilizumab group versus 3296 mg and 3818 mg in the placebo groups ^[196]^A1b. Long‑term follow‑up from GiACTA and real‑world cohorts shows that tocilizumab weekly delays time to flare, reduces cumulative glucocorticoid exposure, and can be discontinued after 1 year with a 47% relapse rate by 18 months off drug ^[149]^A1b^[184]^B2b. Tocilizumab is now recommended by EULAR as adjunctive therapy for patients with refractory or relapsing disease or those at high risk for glucocorticoid‑related adverse events ^[192]^A1c.

Other Promising Agents

Abatacept (CTLA‑4Ig) 10 mg/kg IV on days 1, 15, 29 and week 8, plus prednisone, yielded a 12‑month relapse‑free survival of 48% versus 31% with placebo (P = 0.049) in a 49‑patient trial ^[194]^A1b. Secukinumab (anti‑IL‑17A) 300 mg weekly showed a 70% sustained remission rate at week 28 in a phase 2 Bayesian analysis versus 20% in placebo ^[68]^A1b, but the phase 3 GCAptAIN trial failed to meet its primary endpoint at week 52 (25.6% vs 16.9%, P = 0.09) ^[168]^A1b. Mavrilimumab (GM‑CSF receptor antagonist) 150 mg every 2 weeks reduced flare risk by 62% (HR 0.38, 95% CI 0.15-0.92) in a phase 2 trial ^[220]^A1b. Upadacitinib 15 mg once daily with a 26‑week prednisone taper achieved sustained remission at week 52 in 46.4% of patients versus 29.0% with placebo plus a 52‑week taper (P = 0.002) ^[147]^A1b. The Turkish Society for Rheumatology has recently recommended upadacitinib as an alternative to tocilizumab in patients with low cardiovascular risk ^[169]^A1c.

EULAR now recommends against routine use of antiplatelet or anticoagulant therapy for GCA unless indicated for other reasons ^[192]^A1c. The current treatment paradigm centers on rapid initiation of high‑dose glucocorticoids, prompt addition of tocilizumab (or methotrexate as an alternative) in appropriate patients, and a structured taper with careful monitoring for relapse and glucocorticoid‑related complications.

Pearl: The only agents with phase 3 evidence of sustained glucocorticoid‑free remission are tocilizumab and upadacitinib; TNF inhibitors, IL‑1 blockade, and IL‑23 blockade have all failed to show benefit, underscoring the specificity of the IL‑6/JAK‑STAT pathway in GCA pathogenesis.

Prognosis & Natural History

▸Sustained drug-free remission is achieved in only ~25% of GCA patients by 4 years; relapse after discontinuing tocilizumab occurs in nearly half by 18 months.
▸Mortality is highest in the first year after diagnosis (HR 1.51), driven by infection and glucocorticoid burden, and remains elevated in patients with large-vessel involvement.
▸Cerebrovascular events (3.96%) and thoracic aortic aneurysm (HR 13.46) are key vascular complications that worsen prognosis.

! Warning: The first year after diagnosis carries the highest mortality risk, and severe infections are twice as common as in the general population. **Prednisone >10 mg/day at 12 months** is a modifiable risk factor for infection-related death [71].

HY High Yield: Patients with large-vessel GCA have a higher relapse rate and greater glucocorticoid requirements than those with cranial disease alone, but a lower rate of vision loss [7]. However, they carry a substantially elevated risk of thoracic aortic aneurysm and stroke [84,105].

The evolution of treatment from high-dose glucocorticoids to targeted therapies has reshaped the prognosis of giant cell arteritis, but the natural history remains dominated by relapse and glucocorticoid-related morbidity.

Relapse and Remission Patterns

Sustained drug-free remission (SDFR) is achieved by only a minority of patients. In a large Spanish registry (n=872), cumulative rates of SDFR were 6.3% at 2 years, 20.5% at 3 years, and 25.3% at 4 years ^[171]^B2b. Relapses occur in 44% of patients even with prolonged glucocorticoid regimens, and few are attributable to deviations from recommended tapering schedules ^[221]^B3b. Among patients treated with (TCZ) in routine care, the estimated relapse rate 18 months after discontinuation was 47.3% ^[184]^B2b. However, longer TCZ exposure (>12 months) was associated with a significantly lower risk of subsequent relapse (adjusted HR 0.01, 95% CI 0.00-0.28) ^[184]^B2b. Predictors of treatment failure with TCZ include lower baseline doses and worse patient-reported outcomes ^[66]^A1b.

Mortality

GCA is associated with a 1.5-fold increased mortality during the first year after diagnosis (adjusted HR 1.51), with a smaller excess between 1 and 5 years (HR 1.16), but no increased risk beyond 5 years ^[297]^B3b. Population-based data from Ontario showed that the standardized mortality ratio (SMR) rose from 1.22 in 2002 to 1.92 in 2018, driven by poorer outcomes in younger patients (<65 years) and men ^[20]^B2b. In contrast, a Norwegian cohort found no excess overall mortality (SMR 1.05, 95% CI 0.77-1.38), though male sex was associated with worse survival ^[89]^B2b. Mortality is significantly higher in patients with large-vessel involvement (HR 1.89, 95% CI 1.39-2.56) ^[105]^B2b.

Cardiovascular and Cerebrovascular Complications

Cerebrovascular accidents (CVA) occur in 3.96% of patients, predominantly in the vertebrobasilar territory (62.3%), and the risk of death is doubled in those with CVA (18% vs 8.8%) ^[95]^B2b. Factors associated with CVA include transient ischaemic attack, large-vessel involvement, and visual manifestations ^[95]^B2b. Although acute coronary syndrome risk is not increased overall ^[73]^B2b, the cumulative incidence of vascular complications in patients with stenotic large-vessel vasculitis (LVV) is 13.1% at 1 year and 19.5% at 10 years, with stroke as the leading complication (31%) ^[84]^B2b. risk is markedly elevated (HR 13.46, 95% CI 1.78-101.98), but abdominal aortic aneurysm is not ^[105]^B2b.

Infection and Glucocorticoid-Related Harm

Severe infections are 2.1 times more frequent during the first year compared with the general population (incidence rate 11.1/100 patient-years) ^[71]^B2b. Infection-related mortality is increased, particularly in patients with diabetes (HR 3.3) and those receiving prednisone >10 mg/day after 12 months (HR 4.61) ^[71]^B2b. Pneumocystis jirovecii pneumonia, though rare, carries a 29% mortality rate, underscoring the need for prophylaxis in patients on high-dose glucocorticoids ^[6]^C4.

Effect of Targeted Therapy on the Natural Course

Tocilizumab (TCZ) reduces the risk of treatment failure by 80% compared with prednisone alone (OR 0.2, 95% CI 0.1-0.3) ^[66]^A1b. In the GiACTA trial, sustained glucocorticoid-free remission at 52 weeks was achieved in 56% of patients receiving weekly TCZ versus 14% with placebo ^[196]^A1b. TCZ also delays the median time to first flare (577 days for new-onset disease) and reduces cumulative glucocorticoid exposure ^[207]^B2b. In patients with LVV, TCZ-induced complete metabolic response on PET/CT was associated with a lower risk of subsequent aortic dilation (1% vs 18% in those without complete extinction) ^[302]^C4. Upadacitinib 15 mg (but not 7.5 mg) showed superiority over placebo (46.4% vs 29.0% sustained remission at week 52) ^[147]^A1b, while secukinumab (300 mg) and guselkumab failed to meet their primary endpoints ^[68]^A1b^[142]^A1b. Nevertheless, the fragility of many GCA trials is concerning: 56% of significant outcomes have a fragility index ≤3, meaning a shift of just three events could reverse the conclusions ^[206]^A1a.

Predictors of Poor Outcome

Pearl: Cerebrovascular events (3.96%) and thoracic aortic aneurysm (HR 13.46) are key vascular complications that worsen prognosis.

Predictors of Poor Outcome in GCA

Predictor	Outcome	Source
Female sex	Higher risk of treatment failure with prednisone alone (OR 5.2)	^[66]^A1b
Vertebral artery involvement	Higher risk of vascular complication (HR 1.87)	^[84]^B2b
Large-vessel involvement	Increased mortality (HR 1.89) and CVA risk	^[95]^B2b^[105]^B2b
Higher OGUS at diagnosis	Increased relapse rate (IRR 1.85 per point)	^[69]^B2b
Relapsing disease at baseline	Shorter time to flare and higher cumulative glucocorticoid dose	^[149]^A1b
Prednisone >10 mg/day at 12 months	4.6-fold higher infection-related mortality	^[71]^B2b
Diabetes at baseline	3.3-fold higher infection-related mortality	^[71]^B2b
Lower baseline prednisone dose	Increased risk of treatment failure with tocilizumab	^[66]^A1b

Special Populations, Pregnancy & Fertility

▸GCA is extremely rare in children and pregnancy; management relies on glucocorticoids with careful avoidance of teratogenic DMARDs.
▸Elderly patients are at heightened risk for glucocorticoid adverse effects and methotrexate toxicity, especially when taking diuretics or PPIs [102].
▸No specific guidelines exist for immunocompromised patients; enhanced infection prophylaxis is warranted.

! Warning: Methotrexate toxicity in elderly patients on diuretics, PPIs, or levetiracetam can be life-threatening, monitor renal function and consider alternative agents [102].

The prognosis of GCA is influenced by the patient's age and comorbidities, but special populations require tailored approaches that deviate from standard pathways. Because GCA overwhelmingly affects patients older than 50 years, data in younger and pregnant individuals are extremely limited, and most recommendations are extrapolated from adult guidelines or expert opinion.

Pediatrics

GCA is exceptionally rare in children; no case series or trials exist in the provided literature. When suspected, the diagnostic approach follows adult principles, including temporal artery ultrasound and biopsy, but age-adjusted reference ranges for vessel wall thickness are essential because normal values differ. Treatment relies on glucocorticoids, with as a steroid-sparing agent at weight-based doses, though no pediatric-specific dosing guidelines are available. Long-term developmental impact of chronic glucocorticoid use necessitates growth monitoring and bone health prophylaxis.

Pregnancy

GCA uncommonly affects women of reproductive age, but when it does, management must balance disease control with fetal safety. Glucocorticoids remain the cornerstone of acute therapy because they are relatively safe in pregnancy, though high doses increase risks of gestational diabetes, , and preterm delivery. Methotrexate is contraindicated throughout pregnancy and should be stopped at least 3 months before conception. has limited pregnancy safety data; current guidelines do not recommend its use unless no alternative exists ^[219]^A1c. Delivery planning should involve a multidisciplinary team, and postpartum relapse is common, requiring close monitoring. is generally considered safe with doses below 20 mg daily; methotrexate is excreted in breast milk and should be avoided.

Elderly

This group constitutes the vast majority of GCA patients. Age-related physiologic changes increase vulnerability to glucocorticoid adverse effects, including osteoporosis, diabetes, and infection ^[178]^D5. Methotrexate toxicity is a particular concern: patients older than 70 years with lower baseline eGFR who are receiving diuretics, proton pump inhibitors, or have significantly higher risk of life-threatening toxicity ^[102]^B3b. The ACR guidelines recommend using glucocorticoid-sparing agents such as methotrexate or tocilizumab to reduce cumulative steroid exposure, but with careful monitoring of renal function and drug interactions ^[219]^A1c. Tapering should be individualized, aiming for the lowest effective dose to prevent relapse while minimizing adverse effects ^[178]^D5.

Immunocompromised

No specific recommendations exist for GCA in immunocompromised hosts. The use of immunosuppressive therapies, glucocorticoids, methotrexate, tocilizumab, may further increase infection risk, and clinicians should maintain a low threshold for antimicrobial prophylaxis, particularly for Pneumocystis jirovecii pneumonia when glucocorticoid doses exceed 20 mg prednisone equivalent for more than 4 weeks. Vaccination status should be updated before initiating therapy, and live vaccines are contraindicated during immunosuppression.

Pearl: In elderly patients with GCA, the combination of diuretics, proton pump inhibitors, and low eGFR markedly amplifies methotrexate toxicity risk, always check renal function and drug interactions before starting methotrexate, and consider alternative steroid-sparing agents if these risk factors are present ^[102]^B3b.

Prevention, Screening & Surveillance

▸Aortic imaging (CT/MR angiography) at diagnosis and repeated at 5 years detects previously unknown thoracic aortic dilatation in 10-20% of patients.
▸Annual cardiovascular risk assessment with aggressive statin therapy is warranted because underuse of statins is common and relapse independently predicts cardiovascular events.
▸Vaccine responses are blunted by >10 mg/day prednisolone and methotrexate; booster doses of SARS-CoV-2 and recombinant zoster vaccines are essential.

Beyond the considerations for special populations, all patients with GCA require a structured preventive care bundle that addresses aortic surveillance, cardiovascular risk , and infection prevention, each anchored to guideline-graded intervals.

Screening for Aortic Aneurysm

GCA confers a twofold increased risk of aortic aneurysm (adjusted subhazard ratio 1.92, 95% CI 1.52-2.41) ^[288]^B3b, with a 10-year cumulative incidence of large-vessel manifestations of 24.9% in patients diagnosed since 1980 ^[70]^B2b. Aortic aneurysm growth is accelerated, 2.12 mm/year in GCA versus 0.47 mm/year in degenerative aneurysms, a 4.5-fold increase ^[294]^B3b. The EULAR treat-to-target recommendations include prevention of vascular damage as a treatment target ^[195]^A1c. On average, five to ten patients with GCA need one-time aortic imaging to detect one previously unknown thoracic aortic dilatation or aneurysm ^[67]^B2a. Imaging with CT, MR angiography, or PET/CT should be performed at diagnosis (ideally before glucocorticoid therapy, which reduces vascular FDG uptake ^[234]^B3b) and then repeated at 5 years, because the incidence of aneurysm/dissection rises after that interval ^[70]^B2b. Chest radiography alone is insufficiently sensitive ^[67]^B2a.

Cardiovascular Risk Reduction

Despite a lower baseline prevalence of diabetes and higher HDL at GCA diagnosis ^[73]^B2b, patients with GCA develop more new cardiovascular events during follow-up and less frequently achieve target LDL levels ^[104]^B2b. Underuse of is common ^[104]^B2b. Relapse independently predicts future cardiovascular events (OR 5.01, 95% CI 1.55-16.22) ^[104]^B2b. All patients should receive annual using standard calculators (e.g., Framingham, SCORE2), with aggressive statin therapy to target LDL <1.4 mmol/L (<55 mg/dL) for high-risk patients. Antiplatelet therapy for primary prevention lacks trial evidence; a systematic review protocol is ongoing ^[318]^D5. pulse induction, compared with oral glucocorticoids alone, reduces cumulative exposure (median 733 mg vs 1,902 mg) and may lower cardiometabolic toxicity ^[34]^B2b.

Vaccination in the Immunosuppressed

Glucocorticoid-treated patients with GCA have impaired humoral and cellular vaccine responses, particularly those receiving >10 mg/day prednisolone or ^[259]^B2b. SARS-CoV-2 vaccination is safe and immunogenicity is comparable to age-matched controls, but antibody decay is faster in patients on prednisolone ^[246]^B2b. Booster doses are essential, especially for patients with low post-primary titers ^[246]^B2b. is common (RR 2.6) ^[19]^B3b and may itself trigger GCA ^[17]^B2b; the recombinant zoster vaccine should be administered before or during glucocorticoid tapering, ideally ≥2 weeks before immunosuppression initiation. Annual influenza and pneumococcal vaccines are recommended. Live-attenuated vaccines are contraindicated during high-dose immunosuppression.

Bone Protection and Glucocorticoid Morbidity

Osteoporosis is a frequent damage item (22% of patients in one cohort) ^[132]^B2b. All patients starting ≥7.5 mg/day prednisolone for ≥3 months should receive calcium (1,000-1,200 mg/day) and vitamin D (800 IU/day) plus a bisphosphonate (oral alendronate 70 mg weekly, or intravenous zoledronic acid 5 mg annually). The prevalence of glucocorticoid-induced adrenal insufficiency after prednisolone cessation is only 1.9% ^[249]^C4; routine screening is not recommended, but symptoms of adrenal insufficiency (fatigue, weight loss, hypotension) warrant a short Synacthen test.

Patient Education

Patients should be counseled on the importance of adherence to osteoporosis prophylaxis, timely vaccinations, and recognition of aortic aneurysm warning signs (hoarseness, dysphagia, back/chest pain). Weight gain, psychological effects, and infections are the most worrisome glucocorticoid-related adverse effects ^[229]^D5; proactive discussion improves shared decision-making.

Screening Modality	Population	Timing	Guideline Source
CT/MR angiography of thoracic aorta	All GCA patients	At diagnosis and at 5 years	EULAR T2T ^[195]^A1c, ^[70]^B2b
Cardiovascular risk assessment (Framingham/SCORE2)	All GCA patients	Annually	^[104]^B2b
Bone densitometry (DXA)	All patients on glucocorticoids ≥7.5 mg/day × ≥3 months	At baseline and repeat every 1-2 years	^[229]^D5

Pearl: The highest-yield preventive action in GCA is aortic imaging at diagnosis and at 5 years, because aneurysm detection (NNT 5-10) reduces mortality from rupture (SMR 2.63, 95% CI 1.78-3.73) ^[67]^B2a, ^[70]^B2b.

References

[1]
Patel NJ, Tozzo V, Higgins JM et al.. “The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36383175 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[2]
Saraux A, Le Henaff C, Dernis E et al.. “Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial.” The Lancet. Rheumatology (2023). PMID: 38251563 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[3]
Matza MA, Fernandes AD, Stone JH et al.. “Ustekinumab for the Treatment of Giant Cell Arteritis.” Arthritis care & research (2021). PMID: 32248659 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
[4]
Prieto-González S, Depetris M, García-Martínez A et al.. “Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study.” Annals of the rheumatic diseases (2014). PMID: 24665112 ↗
L3CASE_CONTROLCited in: Definition, Classification & Nomenclature
[5]
Rubenstein E, Maldini C, Gonzalez-Chiappe S et al.. “Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis.” Rheumatology (Oxford, England) (2020). PMID: 31529073 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[6]
Kermani TA, Ytterberg SR, Warrington KJ. “Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series.” Arthritis care & research (2011). PMID: 21240966 ↗
L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
[7]
Muratore F, Kermani TA, Crowson CS et al.. “Large-vessel giant cell arteritis: a cohort study.” Rheumatology (Oxford, England) (2014). PMID: 25193809 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment, Prognosis & Natural History
[8]
Therkildsen P, de Thurah A, Nielsen BD et al.. “Increased risk of thoracic aortic complications among patients with giant cell arteritis: a nationwide, population-based cohort study.” Rheumatology (Oxford, England) (2022). PMID: 34918058 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
[9]
Sanchez-Alvarez C, Bond M, Soowamber M et al.. “Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force.” RMD open (2023). PMID: 37349123 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[10]
Ponte C, Grayson PC, Robson JC et al.. “2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis.” Annals of the rheumatic diseases (2022). PMID: 36351706 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[11]
Bauer CJ, Chrysidis S, Dejaco C et al.. “Exploring the limit of image resolution for human expert classification of vascular ultrasound images in giant cell arteritis and healthy subjects: the GCA-US-AI project.” Annals of the rheumatic diseases (2025). PMID: 40514330 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[12]
De Miguel E, Karalilova R, Macchioni P et al.. “Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica.” Annals of the rheumatic diseases (2024). PMID: 37932008 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease
[13]
Soowamber ML, Bond M, Touma Z et al.. “A glossary of signs and symptoms of giant cell arteritis.” Annals of the rheumatic diseases (2025). PMID: 40731213 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation
[14]
Mukhtyar CB, Beadsmoore C, Coath FL et al.. “Incidence of primary large vessel vasculitis in Norfolk, UK from 2011 to 2020.” Annals of the rheumatic diseases (2023). PMID: 37399329 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[15]
Grayson PC, Maksimowicz-McKinnon K, Clark TM et al.. “Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis.” Annals of the rheumatic diseases (2012). PMID: 22328740 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[16]
Ponte C, Grayson PC, Robson JC et al.. “2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 36350123 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[17]
England BR, Mikuls TR, Xie F et al.. “Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28853238 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prevention, Screening & Surveillance
[18]
Saadoun D, Garrido M, Comarmond C et al.. “Th1 and Th17 cytokines drive inflammation in Takayasu arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 25604824 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease
[19]
Petri H, Nevitt A, Sarsour K et al.. “Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities.” Arthritis care & research (2015). PMID: 25132663 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
[20]
Barra L, Pope JE, Pequeno P et al.. “Increased Mortality for Individuals With Giant Cell Arteritis: A Population-Based Study.” Arthritis care & research (2022). PMID: 33544963 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prognosis & Natural History
[21]
Gribbons KB, Ponte C, Carette S et al.. “Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis.” Arthritis care & research (2020). PMID: 31444857 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[22]
Muratore F, Cavazza A, Boiardi L et al.. “Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study.” Arthritis care & research (2016). PMID: 26415044 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[23]
Bosch P, Espigol-Frigolé G, Cid MC et al.. “Cranial involvement in giant cell arteritis.” The Lancet. Rheumatology (2024). PMID: 38574747 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
[24]
Cacoub P, Vieira M, Langford CA et al.. “Large-vessel vasculitis.” Lancet (London, England) (2025). PMID: 40939604 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[25]
Kermani TA, Warrington KJ. “Polymyalgia rheumatica.” Lancet (London, England) (2012). PMID: 23051717 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prognosis & Natural History
[26]
Schmidt WA, Dasgupta B, Sloane J et al.. “A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.” Arthritis research & therapy (2023). PMID: 37840134 ↗
L1RCTCited in: Definition, Classification & Nomenclature
[27]
Pouncey AL, Yeldham G, Magan T et al.. “Halo sign on temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis.” The Cochrane database of systematic reviews (2024). PMID: 38323659 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[28]
Penet T, Lambert M, Baillet C et al.. “Giant cell arteritis-related cerebrovascular ischemic events: a French retrospective study of 271 patients, systematic review of the literature and meta-analysis.” Arthritis research & therapy (2023). PMID: 37420252 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[29]
Shah S, Rao S, Mackie SL et al.. “A history of polymyalgia rheumatica: a narrative review.” Rheumatology (Oxford, England) (2025). PMID: 39412500 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
[30]
Fernández-Lozano D, Domínguez-Álvaro M, Narváez J et al.. “Sex differences among patients with giant cell arteritis: insights from the Spanish ARTESER Registry.” Rheumatology (Oxford, England) (2026). PMID: 41452742 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
[31]
Chanson N, Galvagni A, Ramos-Casals M et al.. “Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course.” Rheumatology (Oxford, England) (2025). PMID: 39714261 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment
[32]
Wiberg F, Naderi N, Mohammad AJ et al.. “Evaluation of revised classification criteria for giant cell arteritis and its clinical phenotypes.” Rheumatology (Oxford, England) (2021). PMID: 33871583 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Pregnancy & Fertility
[33]
Cutolo M, Soldano S, Smith V et al.. “Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases.” Nature reviews. Rheumatology (2025). PMID: 40721670 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[34]
Fernández-Guitián R, Royuela A, Tornero-Romero F et al.. “Methylprednisolone pulses are associated with faster remission in Giant Cell Arteritis: a multicentre inception cohort study.” Arthritis research & therapy (2026). PMID: 41862996 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
[35]
Dhrif O, Caudron C, Parreau S et al.. “Stroke characteristics in giant cell arteritis and Takayasu arteritis: A multicenter retrospective cohort study of 108 patients.” Seminars in arthritis and rheumatism (2026). PMID: 41702324 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
[36]
Fernández-Lozano D, Hernández-Rodríguez I, Narvaez J et al.. “Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register.” RMD open (2024). PMID: 38531620 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[37]
van Nieuwland M, van Bon L, Vermeer M et al.. “External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic.” RMD open (2023). PMID: 37507207 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[38]
Molina-Collada J, Castrejón I, Monjo I et al.. “Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care.” RMD open (2023). PMID: 37094980 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[39]
Osiowski A, Osiowski M, Stolarz K et al.. “Headache as the most common manifestation of giant cell arteritis?: a systematic review with meta-analysis.” Rheumatology international (2025). PMID: 39932568 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[40]
Borrego-Yaniz G, Ortiz-Fernández L, Madrid-Paredes A et al.. “Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study.” The Lancet. Rheumatology (2024). PMID: 38734017 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[41]
Iwasaki T, Watanabe R, Zhang H et al.. “Identification of the VLDLR locus associated with giant cell arteritis and the possible causal role of low-density lipoprotein cholesterol in its pathogenesis.” Rheumatology (Oxford, England) (2024). PMID: 38317496 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism
[42]
Kastrati K, Aletaha D, Burmester GR et al.. “A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.” RMD open (2022). PMID: 36260501 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[43]
Aletaha D, Kerschbaumer A, Kastrati K et al.. “Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.” Annals of the rheumatic diseases (2022). PMID: 35953263 ↗
L1OTHERCited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, Prevention, Screening & Surveillance
[44]
Karabayas M, Ibrahim HE, Roelofs AJ et al.. “Vascular disease persistence in giant cell arteritis: are stromal cells neglected?” Annals of the rheumatic diseases (2024). PMID: 38684323 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[45]
Corbera-Bellalta M, Kamberovic F, Alba-Rovira R et al.. “The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritis.” Annals of the rheumatic diseases (2025). PMID: 40074597 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[46]
Miyabe C, Miyabe Y, Strle K et al.. “An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.” Annals of the rheumatic diseases (2016). PMID: 27927642 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[47]
Ciccia F, Macaluso F, Mauro D et al.. “New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?” The Lancet. Rheumatology (2021). PMID: 38287633 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[48]
Salvarani C, Cantini F, Hunder GG. “Polymyalgia rheumatica and giant-cell arteritis.” Lancet (London, England) (2008). PMID: 18640460 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[49]
Mehrpoor G, Gargari OK, Khorasani S et al.. “Varicella Zoster Virus in Giant Cell Arteritis: Evidence From a Systematic Review and Meta-Analytic Synthesis.” Reviews in medical virology (2026). PMID: 41450088 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[50]
Neiroukh D, Hajdarpasic A, Ayhan C et al.. “Gut Microbial Taxonomy and Its Role as a Biomarker in Aortic Diseases: A Systematic Review and Future Perspectives.” Journal of clinical medicine (2024). PMID: 39598083 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism
[51]
Schäfer VS, Brossart P, Warrington KJ et al.. “The role of autoimmunity and autoinflammation in giant cell arteritis: A systematic literature review.” Autoimmunity reviews (2023). PMID: 36990133 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism
[52]
Mirouse A, Cacoub P, Saadoun D. “Regulatory T cells and systemic vasculitis.” Current opinion in rheumatology (2022). PMID: 36508306 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism
[53]
O'Neill L, Molloy ES. “The role of toll like receptors in giant cell arteritis.” Rheumatology (Oxford, England) (2016). PMID: 26893518 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[54]
Cid MC, Ríos-Garcés R, Terrades-García N et al.. “Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.” Rheumatology (Oxford, England) (2020). PMID: 32348525 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
[55]
Terrades-Garcia N, Cid MC. “Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved.” Rheumatology (Oxford, England) (2018). PMID: 29982777 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[56]
Dejaco C, Duftner C, Buttgereit F et al.. “The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.” Rheumatology (Oxford, England) (2017). PMID: 27481272 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
[57]
Cantoni E, Merelli I, Stefanoni D et al.. “Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production.” Rheumatology (Oxford, England) (2023). PMID: 36802235 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[58]
Keser G, Aksu K, Direskeneli H. “Discrepancies between vascular and systemic inflammation in large vessel vasculitis: an important problem revisited.” Rheumatology (Oxford, England) (2018). PMID: 28968895 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[59]
Choy EH, De Benedetti F, Takeuchi T et al.. “Translating IL-6 biology into effective treatments.” Nature reviews. Rheumatology (2020). PMID: 32327746 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
[60]
Dejaco C, Brouwer E, Mason JC et al.. “Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.” Nature reviews. Rheumatology (2017). PMID: 28905861 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[61]
Muratore F, Warrington KJ, Dejaco C et al.. “Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.” Nature reviews. Rheumatology (2026). PMID: 42162376 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease
[62]
Weyand CM, Goronzy JJ. “Immune mechanisms in medium and large-vessel vasculitis.” Nature reviews. Rheumatology (2013). PMID: 24189842 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
[63]
Sandovici M, van der Geest N, van Sleen Y et al.. “Need and value of targeted immunosuppressive therapy in giant cell arteritis.” RMD open (2022). PMID: 35149602 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[64]
Sandovici M, van der Geest KSM, Reitsema RD et al.. “Challenges and Future Trends in Large Vessel Vasculitis.” Circulation (2026). PMID: 42330100 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[65]
Cayrou C, Gallet F, Ly K et al.. “Unraveling giant cell arteritis: From immunopathology to emerging targeted therapies (2026 update).” Autoimmunity reviews (2026). PMID: 42288301 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Special Populations, Pregnancy & Fertility
[66]
Unizony SH, Bao M, Han J et al.. “Treatment failure in giant cell arteritis.” Annals of the rheumatic diseases (2021). PMID: 34049857 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[67]
Mackie SL, Hensor EM, Morgan AW et al.. “Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis.” Annals of the rheumatic diseases (2012). PMID: 23264356 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[68]
Venhoff N, Schmidt WA, Bergner R et al.. “Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet. Rheumatology (2023). PMID: 38251601 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, History and Evolution of Treatment, Prognosis & Natural History
[69]
Monti S, Ponte C, Schäfer VS et al.. “The giant cell arteritis (GCA) ultrasound score (OGUS) at diagnosis and after initial treatment predicts future relapses in GCA patients: results of a multicentre prospective study.” Annals of the rheumatic diseases (2025). PMID: 39919971 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
[70]
Kermani TA, Warrington KJ, Crowson CS et al.. “Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.” Annals of the rheumatic diseases (2012). PMID: 23253927 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prevention, Screening & Surveillance
[71]
Schmidt J, Smail A, Roche B et al.. “Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26815885 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
[72]
Mainbourg S, Addario A, Samson M et al.. “Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis.” Arthritis care & research (2020). PMID: 30951256 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[73]
Udayakumar PD, Chandran AK, Crowson CS et al.. “Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study.” Arthritis care & research (2015). PMID: 25074472 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History, Prevention, Screening & Surveillance
[74]
Kermani TA, Schäfer VS, Crowson CS et al.. “Malignancy risk in patients with giant cell arteritis: a population-based cohort study.” Arthritis care & research (2010). PMID: 20191512 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
[75]
Goulabchand R, Qian AS, Nguyen NH et al.. “Burden, Causes, and Outcomes of Hospitalization in Patients With Giant Cell Arteritis: A US National Cohort Study.” Arthritis care & research (2023). PMID: 36576029 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
[76]
Durand M, Thomas SL. “Incidence of infections in patients with giant cell arteritis: a cohort study.” Arthritis care & research (2012). PMID: 22184094 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
[77]
Rhee RL, Grayson PC, Merkel PA et al.. “Infections and the risk of incident giant cell arteritis: a population-based, case-control study.” Annals of the rheumatic diseases (2016). PMID: 27895041 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
[78]
Sattui SE, Conway R, Putman MS et al.. “Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study.” The Lancet. Rheumatology (2021). PMID: 34778843 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History
[79]
Barde F, Pacoureau L, Elbaz A et al.. “Association between cardiovascular risk factors and the occurrence of giant cell arteritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2025). PMID: 40127188 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
[80]
Lai LYH, Harris E, West RM et al.. “Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis.” RMD open (2018). PMID: 29531778 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease
[81]
Gutierrez-Rodrigues F, Wells KV, Jones AI et al.. “Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis.” Annals of the rheumatic diseases (2024). PMID: 38049983 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[82]
Borrego-Yaniz G, Fuentes-Moreno V, Ortiz-Fernández L et al.. “Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.” Annals of the rheumatic diseases (2026). PMID: 42399125 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[83]
Gribbons KB, Ponte C, Craven A et al.. “Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 31729185 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[84]
Maalouf G, Arnould B, Espitia O et al.. “Prognosis and Long-Term Outcome of Stenotic Large Vessel Involvement in Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41728983 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[85]
Martínez-Gutiérrez L, Borrego-Yaniz G, Hernández-Rodríguez J et al.. “Higher Complement C4 Gene Copy Number Constitutes a Shared Genetic Risk Factor for Giant Cell Arteritis and IgA Vasculitis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 42045811 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[86]
Unizony S, Lu N, Tomasson G et al.. “Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28029234 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease
[87]
Chakravarti R, Gupta K, Swain M et al.. “14-3-3 in Thoracic Aortic Aneurysms: Identification of a Novel Autoantigen in Large Vessel Vasculitis.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 25917817 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[88]
Hemmig AK, Aschwanden M, Seiler S et al.. “Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study.” RMD open (2023). PMID: 36635003 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[89]
Andersen JB, Myklebust G, Haugeberg G et al.. “Incidence Trends and Mortality of Giant Cell Arteritis in Southern Norway.” Arthritis care & research (2021). PMID: 31909871 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[90]
Muratore F, Kermani TA, Crowson CS et al.. “Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease?” Arthritis care & research (2018). PMID: 29266882 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
[91]
Saadoun D, Vieira M, Vautier M et al.. “SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study.” The Lancet. Rheumatology (2021). PMID: 33942031 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
[92]
Dhivagaran T, Butt FR, Nasri D et al.. “Prevalence of diplopia among giant cell arteritis patients: a systematic review and meta-analysis.” Eye (London, England) (2026). PMID: 41572017 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[93]
Martínez-Gutiérrez L, Rodriguez-Martin I, Borrego-Yaniz G et al.. “Cross-Trait Meta-Analysis Reveals a Genetic Link between Inflammation and Aging in Giant Cell Arteritis.” Aging and disease (2025). PMID: 40901985 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
[94]
Sullivan MM, Mead-Harvey C, Sartori-Valinotti JC et al.. “Vasculitis associated with VEXAS syndrome.” Rheumatology (Oxford, England) (2025). PMID: 39392442 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[95]
Martín-Gutiérrez A, Molina-Collada J, Domínguez-Álvaro M et al.. “Cerebrovascular accidents in giant cell arteritis: prevalence and predictive factors from the ARTESER registry.” Rheumatology (Oxford, England) (2025). PMID: 39918980 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[96]
Barra L, Pope JE, Pequeno P et al.. “Incidence and prevalence of giant cell arteritis in Ontario, Canada.” Rheumatology (Oxford, England) (2020). PMID: 32249899 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[97]
Greigert H, Mounier M, Arnould L et al.. “Heamatological malignancies in giant cell arteritis: a French population-based study.” Rheumatology (Oxford, England) (2021). PMID: 33792672 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[98]
Narváez J, Domínguez-Álvaro M, Hernández-Rodríguez I et al.. “Epidemiology of major and minor relapses in giant cell arteritis according to EULAR definitions: insights from the ARTESER registry.” Rheumatology (Oxford, England) (2025). PMID: 40343487 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[99]
Watts RA, Hatemi G, Burns JC et al.. “Global epidemiology of vasculitis.” Nature reviews. Rheumatology (2021). PMID: 34853411 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[100]
Soriano A, Muratore F, Pipitone N et al.. “Visual loss and other cranial ischaemic complications in giant cell arteritis.” Nature reviews. Rheumatology (2017). PMID: 28680132 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
[101]
Nitzan I, Shemesh N, Kubovsky S et al.. “Incidence of Giant Cell Arteritis Following Herpes Zoster Ophthalmicus: A Multicenter Retrospective Cohort Study.” American journal of ophthalmology (2025). PMID: 40414592 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[102]
Kumar C, Kuhn M, Herrmann K et al.. “Severe methotrexate toxicity in elderly patients under diuretics.” RMD open (2024). PMID: 38176739 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Fertility
[103]
Guedon AF, Ouafdi A, Belfeki N et al.. “Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis.” RMD open (2024). PMID: 39658053 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[104]
Jud P, Hafner F, Meinitzer A et al.. “Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis.” RMD open (2023). PMID: 37657846 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
[105]
Elfishawi MM, Kaymakci MS, J Achenbach S et al.. “Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years.” RMD open (2024). PMID: 38331471 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[106]
Besutti G, Marvisi C, Mancuso P et al.. “Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: a matched cross-sectional study.” RMD open (2023). PMID: 37640517 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[107]
Zhu LM, Mendel A, Ross C et al.. “The effectiveness and safety of leflunomide in the treatment of giant cell arteritis: a systematic review and meta-analysis.” Rheumatology advances in practice (2025). PMID: 41323363 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[108]
Dhrif O, Lahmar W, Achour TB et al.. “Seasonality and latitude as linked environmental factors in giant cell arteritis incidence: a systematic review and meta-analysis.” Rheumatology international (2025). PMID: 41128917 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[109]
Horiuchi S, Kudo Y, Kawano K et al.. “Risk factors of serious infections in patients with large-vessel vasculitis after the approval of tocilizumab in 2017: a retrospective nested case-control study using the Japanese health insurance database.” Arthritis research & therapy (2026). PMID: 41764518 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors
[110]
Sørensen MER, Lindhardt Petersen SS, Overgaard AL et al.. “The impact of interleukin-6 receptor inhibitors on risk of diabetes mellitus in patients with giant cell arteritis: a cohort study.” Rheumatology international (2026). PMID: 42362950 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[111]
Lakrafi Y, Moudatir M, Echchilali K et al.. “Treatment-resistant arterial hypertension revealing giant cell arteritis: A case report.” The American journal of medicine (2026). PMID: 41791692 ↗
L4CASE_REPORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[112]
Ortiz-Fernández L, Carmona FD, López-Mejías R et al.. “Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis.” Annals of the rheumatic diseases (2018). PMID: 29374629 ↗
L3SR_OBSCited in: Clinical Presentation
[113]
Delaval L, Samson M, Schein F et al.. “Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A Case-Control Study.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32951354 ↗
L3CASE_CONTROLCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[114]
Emmi G, Bagni G, Lastraioli E et al.. “A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome.” Annals of the rheumatic diseases (2021). PMID: 34844932 ↗
L3OTHERCited in: Clinical Presentation, Prevention, Screening & Surveillance
[115]
Veroutis D, Argyropoulou OD, Goules AV et al.. “Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways.” Annals of the rheumatic diseases (2024). PMID: 38050005 ↗
L3OTHERCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[116]
Ehlers L, Askling J, Bijlsma HW et al.. “2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.” Annals of the rheumatic diseases (2019). PMID: 30898837 ↗
L1REVIEW_NARRATIVECited in: Clinical Presentation
[117]
Cowley S, Harkins P, Kirby C et al.. “Should all patients with polymyalgia rheumatica have a vascular ultrasound assessment?” Annals of the rheumatic diseases (2024). PMID: 38553044 ↗
L5OTHERCited in: Clinical Presentation, Prevention, Screening & Surveillance
[118]
Robinette ML, Weeks LD, Kramer RJ et al.. “Association of Somatic TET2 Mutations With Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 37909388 ↗
L2OTHERCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[119]
Alba MA, Unizony S, Warrington KJ et al.. “Management of Relapses in Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 39711085 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[120]
Jiemy WF, van Sleen Y, Graver JC et al.. “Indication of Activated Senescence Pathways in the Temporal Arteries of Patients With Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37057491 ↗
L4OTHERCited in: Clinical Presentation
[121]
Clifford AH, Arafat A, Idrees JJ et al.. “Outcomes Among 196 Patients With Noninfectious Proximal Aortitis.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30730604 ↗
L4OTHERCited in: Clinical Presentation
[122]
Desbois AC, Régnier P, Quiniou V et al.. “Specific Follicular Helper T Cell Signature in Takayasu Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33538119 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[123]
Maughan RT, Macdonald-Dunlop E, Haroon-Rashid L et al.. “Proteomic Profiling of the Large-Vessel Vasculitis Spectrum Identifying Shared Signatures of Innate Immune Activation and Stromal Remodeling.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 39817309 ↗
L3OTHERCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[124]
Putman MS, Gribbons KB, Ponte C et al.. “Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis.” Arthritis care & research (2022). PMID: 33338326 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[125]
Sebastian A, van der Geest KSM, Tomelleri A et al.. “Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study.” The Lancet. Rheumatology (2024). PMID: 38554720 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[126]
Beck DB, Ferrada MA, Sikora KA et al.. “Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.” The New England journal of medicine (2020). PMID: 33108101 ↗
L4OTHERCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[127]
Chen RY, Mandzia J, Barra L. “Cognitive impairment and other neuropsychiatric manifestations in patients with primary vasculitis: a systematic review.” Seminars in arthritis and rheumatism (2025). PMID: 40784139 ↗
L2SR_OBSCited in: Clinical Presentation
[128]
Junek ML, Okaj I, Patel S et al.. “Multivariable Models to Predict a Diagnosis of Giant Cell Arteritis: Systematic Review and Metaanalysis.” The Journal of rheumatology (2025). PMID: 40592550 ↗
L2SR_OBSCited in: Clinical Presentation
[129]
Vodopivec I, Rizzo JF. “Ophthalmic manifestations of giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29986083 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[130]
Blanco R, Aldasoro V, Maiz O et al.. “Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases.” Rheumatology (Oxford, England) (2025). PMID: 39658241 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[131]
Kern D, Bley TA, Riedling L et al.. “Vascular MRI also depicts musculoskeletal manifestations in giant-cell arteritis-polymyalgia rheumatica spectrum disease patients.” Rheumatology (Oxford, England) (2025). PMID: 40131396 ↗
L4OTHERCited in: Clinical Presentation
[132]
Kermani TA, Sreih AG, Cuthbertson D et al.. “Evaluation of damage in giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29112740 ↗
L2OTHERCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
[133]
Petzinna SM, Burg LC, Bauer CJ et al.. “Transorbital ultrasound in the diagnosis of giant cell arteritis.” Rheumatology (Oxford, England) (2024). PMID: 38759118 ↗
L2OTHERCited in: Clinical Presentation
[134]
Salvarani C, Pipitone N, Versari A et al.. “Clinical features of polymyalgia rheumatica and giant cell arteritis.” Nature reviews. Rheumatology (2012). PMID: 22825731 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[135]
Molina-Collada J, Castrejón I, Monjo-Henry I et al.. “Impact of ultrasound limitation to assess aortitis in patients with giant cell arteritis: comparative study with FDG-PET/CT.” RMD open (2023). PMID: 37597848 ↗
L4OTHERCited in: Clinical Presentation
[136]
Azoyan L, Bonjour M, Steichen O. “Diagnostic Accuracy of Clinical Findings for Takayasu Arteritis: A Rapid Review and Meta-Analysis.” International journal of vascular medicine (2025). PMID: 40963697 ↗
L2SR_OBSCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target
[137]
Kawamoto T, Ogasawara M, Nojiri S et al.. “Clinical characteristics of giant cell arteritis with ocular involvement: A single-centre retrospective study.” Modern rheumatology (2026). PMID: 41714188 ↗
L3COHORTCited in: Clinical Presentation
[138]
Shahid F, Farooq H, Abeer H et al.. “The Association of Polymyalgia Rheumatica and Giant Cell Arteritis With COVID-19 Vaccination: A Systematic Review.” Clinical medicine insights. Arthritis and musculoskeletal disorders (2026). PMID: 41567360 ↗
L4SR_OBSCited in: Clinical Presentation
[139]
Rubinsztajn A, Parreau S, Sailler L et al.. “Characteristics of patients with major relapse in giant cell arteritis: a multicenter case-control study.” Clinical rheumatology (2025). PMID: 41310094 ↗
L3CASE_CONTROLCited in: Clinical Presentation
[140]
Dejaco C, Ramiro S, Bond M et al.. “EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update.” Annals of the rheumatic diseases (2024). PMID: 37550004 ↗
L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
[141]
Maz M, Chung SA, Abril A et al.. “2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.” Arthritis care & research (2021). PMID: 34235871 ↗
L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History, Special Populations, Pregnancy & Fertility
[142]
Makhzoum JP, Cid MC, Samson M et al.. “A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis.” Annals of the rheumatic diseases (2026). PMID: 41688258 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
[143]
Dejaco C, Ramiro S, Touma Z et al.. “What is a response in randomised controlled trials in giant cell arteritis?” Annals of the rheumatic diseases (2023). PMID: 36801812 ↗
L5RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[144]
Stone JH, Tuckwell K, Dimonaco S et al.. “Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30835950 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[145]
Dejaco C, Ramiro S, Duftner C et al.. “EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice.” Annals of the rheumatic diseases (2018). PMID: 29358285 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[146]
Villiger PM, Adler S, Kuchen S et al.. “Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2016). PMID: 26952547 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[147]
Blockmans D, Penn SK, Setty AR et al.. “A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.” The New England journal of medicine (2025). PMID: 40174237 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
[148]
Rhéaume M, Rebello R, Pagnoux C et al.. “High-Resolution Magnetic Resonance Imaging of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 27483045 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[149]
Stone JH, Spotswood H, Unizony SH et al.. “New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.” Rheumatology (Oxford, England) (2022). PMID: 34718434 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[150]
Diamantopoulos AP, Haugeberg G, Hetland H et al.. “Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series.” Arthritis care & research (2014). PMID: 24106211 ↗
L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[151]
Bosch P, Bond M, Dejaco C et al.. “Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations.” RMD open (2023). PMID: 37620113 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[152]
Dejaco C, Ponte C, Monti S et al.. “The provisional OMERACT ultrasonography score for giant cell arteritis.” Annals of the rheumatic diseases (2022). PMID: 36600183 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[153]
Koster MJ, Crowson CS, Giblon RE et al.. “Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.” Annals of the rheumatic diseases (2022). PMID: 35190385 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
[154]
Segarra M, García-Martínez A, Sánchez M et al.. “Gelatinase expression and proteolytic activity in giant-cell arteritis.” Annals of the rheumatic diseases (2007). PMID: 17502363 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[155]
Brkic A, Terslev L, Møller Døhn U et al.. “Clinical Applicability of Ultrasound in Systemic Large Vessel Vasculitides.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 31309732 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[156]
van der Geest KSM, Sandovici M, van Sleen Y et al.. “Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29648680 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[157]
Quinn KA, Ahlman MA, Alessi HD et al.. “Association of 18 F-Fluorodeoxyglucose-Positron Emission Tomography Activity With Angiographic Progression of Disease in Large Vessel Vasculitis.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35792044 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[158]
Sammel AM, Hsiao E, Schembri G et al.. “Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double-Blind, Cross-Sectional Study.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30848549 ↗
L1OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
[159]
Unizony S, Arias-Urdaneta L, Miloslavsky E et al.. “Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.” Arthritis care & research (2012). PMID: 22674883 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
[160]
Rimland CA, Quinn KA, Rosenblum JS et al.. “Outcome Measures in Large Vessel Vasculitis: Relationship Between Patient-, Physician-, Imaging-, and Laboratory-Based Assessments.” Arthritis care & research (2020). PMID: 31785185 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[161]
Turkiewicz A, Stamatis P, Mohammad AJ. “Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case-control study.” RMD open (2020). PMID: 32792416 ↗
L3CASE_CONTROLCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[162]
van der Geest KSM, Sandovici M, Bley TA et al.. “Large vessel giant cell arteritis.” The Lancet. Rheumatology (2024). PMID: 38574745 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[163]
Yates M, Davies C, MacGregor AJ. “Improving polymyalgia rheumatica care: considerations for routine vascular ultrasound in clinical practice.” The Lancet. Rheumatology (2025). PMID: 40112839 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
[164]
Nettleton E, Carlson K, Putman M. “The emerging risk of overdiagnosis in rheumatoid arthritis and polymyalgia rheumatica.” The Lancet. Rheumatology (2024). PMID: 39341221 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prevention, Screening & Surveillance
[165]
Espígol-Frigolé G, Dejaco C, Mackie SL et al.. “Polymyalgia rheumatica.” Lancet (London, England) (2023). PMID: 37832573 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
[166]
González-Gay MA, Matteson EL, Castañeda S. “Polymyalgia rheumatica.” Lancet (London, England) (2017). PMID: 28774422 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[167]
Dejaco C, Matteson EL. “Polymyalgia Rheumatica.” The New England journal of medicine (2026). PMID: 41812194 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[168]
Stone JH, Venhoff N, Buttgereit F et al.. “Secukinumab for Giant Cell Arteritis.” NEJM evidence (2026). PMID: 42234457 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[169]
Alibaz-Oner F, Kara M, Esatoglu SN et al.. “Turkish Society for Rheumatology recommendations for the diagnosis, follow-up and management of giant cell arteritis.” Clinical and experimental rheumatology (2026). PMID: 41930660 ↗
L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
[170]
Ponte C, Martins-Martinho J, Luqmani RA. “Diagnosis of giant cell arteritis.” Rheumatology (Oxford, England) (2020). PMID: 32348512 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[171]
Narváez J, Domínguez M, Galíndez E et al.. “Sustained drug-free remission in giant cell arteritis.” Rheumatology (Oxford, England) (2025). PMID: 39589919 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
[172]
Coath FL, Mukhtyar C. “Ultrasonography in the diagnosis and follow-up of giant cell arteritis.” Rheumatology (Oxford, England) (2021). PMID: 33599253 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[173]
Schmidt WA. “Ultrasound in the diagnosis and management of giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29982780 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[174]
Koster MJ, Matteson EL, Warrington KJ. “Large-vessel giant cell arteritis: diagnosis, monitoring and management.” Rheumatology (Oxford, England) (2018). PMID: 29982778 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
[175]
Junek ML, Riaz S, Garner S et al.. “Added diagnostic yield of temporal artery magnetic resonance angiography in the evaluation of giant cell arteritis.” Rheumatology (Oxford, England) (2023). PMID: 36205595 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[176]
Tomelleri A, Bond M, Marvisi C et al.. “Secukinumab is effective and safe for patients with giant cell arteritis after tocilizumab failure.” Rheumatology (Oxford, England) (2025). PMID: 40366735 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment
[177]
Tomelleri A, van der Geest KSM, Khurshid MA et al.. “Disease stratification in GCA and PMR: state of the art and future perspectives.” Nature reviews. Rheumatology (2023). PMID: 37308659 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[178]
Camellino D, Matteson EL, Buttgereit F et al.. “Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.” Nature reviews. Rheumatology (2020). PMID: 32759996 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History, Special Populations, Pregnancy & Fertility
[179]
Han X, He Y, Yang J et al.. “Superior correlation with clinical activity and unique detection patterns: a prospective study of FAPI versus FDG-PET in polymyalgia rheumatica and giant cell arteritis.” European journal of nuclear medicine and molecular imaging (2026). PMID: 42020812 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[180]
Michailidou D, Dejaco C, Ahlman M et al.. “Vascular imaging as an endpoint in clinical trials of giant cell arteritis.” Clinical and experimental rheumatology (2026). PMID: 42018344 ↗
L5TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[181]
Brenac G, Bernard A, Lemogne B et al.. “Orbital MRI for diagnosing giant cell arteritis in cases of anterior ischaemic optic neuropathy.” RMD open (2026). PMID: 41730612 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[182]
Duftner C, Redlinger N, Bruyn GA et al.. “Reliability of the OMERACT Giant cell arteritis Ultrasonography Score (OGUS): results of a patient-based exercise involving experts and non-experts in vascular ultrasonography.” RMD open (2025). PMID: 39753294 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[183]
Schremmer T, Dejaco C, Recker F et al.. “OMERACT GCA phantom project: validation of a 3D-printed ultrasound training phantom for diagnosis of giant cell arteritis.” RMD open (2025). PMID: 39915246 ↗
L5OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[184]
Matza MA, Dagincourt N, Mohan SV et al.. “Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis.” RMD open (2023). PMID: 37024237 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History
[185]
Petzinna SM, von der Emde L, Esser J et al.. “Optical coherence tomography angiography detects retinal microvascular changes in giant cell arteritis: the potential protective role of aortitis.” RMD open (2025). PMID: 41213713 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[186]
Tomelleri A, Dejaco C. “New blood biomarkers and imaging for disease stratification and monitoring of giant cell arteritis.” RMD open (2024). PMID: 38395453 ↗
L5OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[187]
Seitz L, Bucher S, Bütikofer L et al.. “DWI scrolling artery sign for the diagnosis of giant cell arteritis: a pattern recognition approach.” RMD open (2024). PMID: 38519109 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[188]
Schmalzing M, Froehlich M, Strunz PP et al.. “Calprotectin and serum amyloid A for disease activity assessment in giant cell arteritis and polymyalgia rheumatica: results from a prospective single-centre cohort study.” Rheumatology international (2026). PMID: 41779206 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[189]
Ichimata S, Yoshinaga T, Sato M et al.. “Giant Cell Arteritis With Medin-Derived Amyloid (AMed) Deposition in a Patient With COVID-19: An Autopsy Case.” Pathology international (2026). PMID: 41795795 ↗
L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
[190]
Glynn T, Leech MT, Goergen SK et al.. “A Diagnostic Headache.” The Medical journal of Australia (2026). PMID: 41772926 ↗
L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Special Populations, Pregnancy & Fertility
[191]
Beydon M, Lacaille D, Fautrel B et al.. “Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database.” RMD open (2026). PMID: 42414038 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
[192]
Hellmich B, Agueda A, Monti S et al.. “2018 Update of the EULAR recommendations for the management of large vessel vasculitis.” Annals of the rheumatic diseases (2019). PMID: 31270110 ↗
L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History
[193]
Quinn KA, Tan S, Verdijk P et al.. “18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment Within a Randomized Controlled Trial in Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41940456 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[194]
Langford CA, Cuthbertson D, Ytterberg SR et al.. “A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28133925 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
[195]
Dejaco C, Kerschbaumer A, Aletaha D et al.. “Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.” Annals of the rheumatic diseases (2024). PMID: 36828585 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History, Prevention, Screening & Surveillance
[196]
Stone JH, Tuckwell K, Dimonaco S et al.. “Trial of Tocilizumab in Giant-Cell Arteritis.” The New England journal of medicine (2017). PMID: 28745999 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[197]
Alessi HD, Quinn KA, Ahlman MA et al.. “Longitudinal Characterization of Vascular Inflammation and Disease Activity in Takayasu Arteritis and Giant Cell Arteritis: A Single-Center Prospective Study.” Arthritis care & research (2023). PMID: 35762866 ↗
L2COHORTCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[198]
Christ L, Seitz L, Scholz G et al.. “Efficacy of tocilizumab monotherapy after ultrashort glucocorticoid administration to treat giant cell arteritis: three-year follow-up.” Rheumatology (Oxford, England) (2025). PMID: 40478774 ↗
L4TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
[199]
Hysa E, Bond M, Ehlers L et al.. “Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review.” Rheumatology (Oxford, England) (2024). PMID: 37672017 ↗
L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prevention, Screening & Surveillance
[200]
Duftner C, Dejaco C, Sepriano A et al.. “Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations.” RMD open (2018). PMID: 29531788 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification
[201]
van der Geest KS, Abdulahad WH, Chalan P et al.. “Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24623536 ↗
L3OTHERCited in: Severity, Disease Activity & Risk Stratification
[202]
Grayson PC, Alehashemi S, Bagheri AA et al.. “18 F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29145713 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification
[203]
Secada-Gómez C, Loricera J, Martín-Gutiérrez A et al.. “Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients.” Arthritis care & research (2026). PMID: 41531143 ↗
L3OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
[204]
Xu S, Jiemy WF, Boots AMH et al.. “Altered Plasma Levels and Tissue Expression of Fibroblast Activation Protein Alpha in Giant Cell Arteritis.” Arthritis care & research (2024). PMID: 38685696 ↗
L3OTHERCited in: Severity, Disease Activity & Risk Stratification
[205]
García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G et al.. “Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.” Arthritis care & research (2010). PMID: 20535794 ↗
L4OTHERCited in: Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related
[206]
Misra DP, Mukhtyar CB, Chandwar K et al.. “The fragility of randomized controlled trials in large vessel vasculitis.” Autoimmunity reviews (2025). PMID: 40865894 ↗
L1SR_MA_RCTCited in: Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
[207]
Stone JH, Han J, Aringer M et al.. “Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.” The Lancet. Rheumatology (2021). PMID: 38279390 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[208]
Unizony S, Matza MA, Jarvie A et al.. “Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study.” The Lancet. Rheumatology (2023). PMID: 38251564 ↗
L4OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
[209]
Christ L, Seitz L, Scholz G et al.. “Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study.” The Lancet. Rheumatology (2021). PMID: 38287611 ↗
L4OTHERCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
[210]
Stone JH, Buttgereit F, Saraux A et al.. “Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.” The New England journal of medicine (2026). PMID: 42234540 ↗
L1OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
[211]
Borresen SW, Hansen SB, Al-Jorani H et al.. “Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency: a study protocol for a multicentre, randomised, double-blinded, placebo-controlled clinical trial on health-related quality of life in patients with polymyalgia rheumatica/giant cell arteritis on low-dose prednisolone treatment (the RESCUE study).” BMJ open (2026). PMID: 42276802 ↗
L5TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
[212]
Dreyer AF, Hansen SB, Borresen SW et al.. “Hydrocortisone replacement therapy in patients with glucocorticoid withdrawal syndrome after cessation of glucocorticoid treatment: REPLACE, a multicentre, randomised, double-blinded, placebo-controlled, 16-week study protocol.” BMJ open (2026). PMID: 41638742 ↗
L5TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
[213]
Samson M, Fournel I, Bourredjem A et al.. “Immediate versus gradual TocilizuMab discontinuAtion in GIant Cell Arteritis: protocol of the multicentre randomised open-label MAGICA trial.” BMJ open (2025). PMID: 41067765 ↗
L5TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[214]
Antonio AA, Santos RN, Abariga SA. “Tocilizumab for giant cell arteritis.” The Cochrane database of systematic reviews (2022). PMID: 35560150 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
[215]
Antonio AA, Santos RN, Abariga SA. “Tocilizumab for giant cell arteritis.” The Cochrane database of systematic reviews (2021). PMID: 34420204 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
[216]
Clifford AH, Thai J, Yip A et al.. “Follow-Up 18F-Fluorodeoxyglucose Positron Emission Tomography in Treated Patients With Giant Cell Arteritis: A Systematic Review and Metaanalysis.” The Journal of rheumatology (2026). PMID: 42140639 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[217]
Dejaco C, Singh YP, Perel P et al.. “2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.” Annals of the rheumatic diseases (2015). PMID: 26359488 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
[218]
Keller KK, Mukhtyar CB, Nielsen AW et al.. “Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group.” Annals of the rheumatic diseases (2024). PMID: 38050004 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
[219]
Maz M, Chung SA, Abril A et al.. “2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34235884 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
[220]
Cid MC, Unizony SH, Blockmans D et al.. “Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.” Annals of the rheumatic diseases (2022). PMID: 35264321 ↗
L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[221]
Felten L, Leuchten N, Aringer M. “Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study.” Rheumatology (Oxford, England) (2022). PMID: 34487149 ↗
L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
[222]
Therkildsen P, Nielsen BD, de Thurah A et al.. “All-cause and cause-specific mortality in patients with giant cell arteritis: a nationwide, population-based cohort study.” Rheumatology (Oxford, England) (2022). PMID: 34164660 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
[223]
Mensch N, Hemmig AK, Aschwanden M et al.. “Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study.” RMD open (2023). PMID: 37460275 ↗
L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
[224]
Ricordi C, Marvisi C, Macchioni P et al.. “Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies.” RMD open (2024). PMID: 39740930 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[225]
Carnota-Méndez P, Remolí-Sargues L, Copete S et al.. “Clinical Guidelines for the Diagnosis and Management of Retinal Artery Occlusions by the Spanish Society of Retina and Vitreous.” Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (2026). PMID: 41818386 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
[226]
Schenning LCM, van Onna M, Tas SW. “Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits.” The Lancet. Rheumatology (2025). PMID: 41418799 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
[227]
Mackie SL, Brouwer E, Conway R et al.. “Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective.” The Lancet. Rheumatology (2020). PMID: 33521671 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[228]
Guemara R, Pieren A, Brulhart L. “Angioinvasive aspergillosis mimicking giant cell arteritis in an 81-year-old man with jaw pain and vision loss.” RMD open (2022). PMID: 36418085 ↗
L4CASE_REPORTCited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
[229]
Buttgereit F, Matteson EL, Dejaco C et al.. “Prevention of glucocorticoid morbidity in giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29982779 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
[230]
Baral B, Parajuli M, Pinilla J et al.. “Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” ARP rheumatology (2025). PMID: 40629823 ↗
L1SR_MA_RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
[231]
Schweiger L, Meinitzer A, Szolar D et al.. “Correlation and Risk Assessment of Inflammation-Based Parameters on Cardiovascular Parameters and Clinical Events in Giant Cell Arteritis: A Retrospective Study.” International journal of molecular sciences (2025). PMID: 40725261 ↗
L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
[232]
Evans J, Steel L, Borg F et al.. “Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis.” RMD open (2016). PMID: 26819753 ↗
L5OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
[233]
Esen I, Arends S, Dalsgaard Nielsen B et al.. “Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort.” RMD open (2023). PMID: 36631159 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[234]
Malich L, Gühne F, Hoffmann T et al.. “Distribution patterns of arterial affection and the influence of glucocorticoids on 18F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis.” RMD open (2022). PMID: 35953239 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Prevention, Screening & Surveillance
[235]
Prieto-González S, Terrades-García N, Corbera-Bellalta M et al.. “Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.” RMD open (2017). PMID: 29299342 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[236]
Buttgereit F, Boyadzhieva Z, Reisch M et al.. “[S2e guidelines on the treatment of polymyalgia rheumatica: update 2024 : Evidence-based guidelines of the German Society for Rheumatology and Clinical Immunology (DGRh), the Austrian Society for Rheumatology and Rehabilitation (ÖGR) and the Swiss Society for Rheumatology (SGR) and the participating medical scientific specialist societies and other organizations].” Zeitschrift fur Rheumatologie (2025). PMID: 40560440 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
[237]
Seror R, Baron G, Hachulla E et al.. “Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.” Annals of the rheumatic diseases (2013). PMID: 23897775 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[238]
Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L et al.. “A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.” Annals of the rheumatic diseases (2007). PMID: 18086726 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[239]
Adler S, Reichenbach S, Gloor A et al.. “Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.” Rheumatology (Oxford, England) (2019). PMID: 30915462 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[240]
Gloor AD, Yerly D, Adler S et al.. “Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29961816 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[241]
Reichenbach S, Adler S, Bonel H et al.. “Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29529280 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[242]
Visvanathan S, Rahman MU, Hoffman GS et al.. “Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.” Rheumatology (Oxford, England) (2011). PMID: 21873264 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[243]
Monti S, Águeda AF, Luqmani RA et al.. “Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.” RMD open (2019). PMID: 31673411 ↗
L2SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
[244]
Chaddock NJM, Harden CJ, Sorensen L et al.. “Age, anticoagulants, hypertension and cardiovascular genetic traits predict cranial ischaemic complications in patients with giant cell arteritis.” Annals of the rheumatic diseases (2025). PMID: 39919905 ↗
L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[245]
Lozano E, Segarra M, García-Martínez A et al.. “Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis.” Annals of the rheumatic diseases (2007). PMID: 17584806 ↗
L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[246]
van Sleen Y, van der Geest KSM, Buisman AM et al.. “Humoral SARS-CoV-2 Vaccine Responses in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica: Decay After Primary Vaccination and Effects of the Booster.” Arthritis care & research (2023). PMID: 37332051 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Prevention, Screening & Surveillance
[247]
Scolnik M, Brance ML, Fernández-Ávila DG et al.. “Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis.” The Lancet. Rheumatology (2022). PMID: 38261393 ↗
L1REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[248]
de Boysson H, Ly KH, Geffray L et al.. “Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial.” Arthritis research & therapy (2025). PMID: 40483523 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[249]
Hansen SB, Dreyer AF, Jørgensen NT et al.. “Changes in Adrenal Function and Insufficiency Symptoms After Cessation of Prednisolone.” JAMA network open (2025). PMID: 40100216 ↗
L4RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prevention, Screening & Surveillance
[250]
Deshayes S, Ly KH, Rieu V et al.. “Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments.” Rheumatology (Oxford, England) (2021). PMID: 33742671 ↗
L4CASE_REPORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[251]
Xu C, Denney WS, Liu Y et al.. “Population Pharmacokinetics and Exposure-Response Analyses of Sarilumab in Patients with Polymyalgia Rheumatica.” Journal of clinical pharmacology (2025). PMID: 40105153 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[252]
Shirai T, Yoshida T, Sugano E et al.. “Systematic Review and Meta-Analysis for JCS 2026 Guideline on Management of Large-Vessel Vasculitis.” Circulation journal : official journal of the Japanese Circulation Society (2026). PMID: 41692437 ↗
L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[253]
Rousset S, Treiner E, Moulis G et al.. “High rate of indeterminate results of the QuantiFERON-TB Gold in-tube test, third generation, in patients with systemic vasculitis.” Rheumatology (Oxford, England) (2020). PMID: 31518431 ↗
L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[254]
Quick V, Abusalameh M, Ahmed S et al.. “Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England.” Rheumatology (Oxford, England) (2024). PMID: 37952183 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[255]
van der Geest KS, Abdulahad WH, Rutgers A et al.. “Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.” Rheumatology (Oxford, England) (2015). PMID: 25724206 ↗
L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[256]
Mahr A, Belhassen M, Paccalin M et al.. “Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data.” Rheumatology (Oxford, England) (2020). PMID: 31382293 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[257]
Schönau V, Roth J, Tascilar K et al.. “Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study.” Rheumatology (Oxford, England) (2021). PMID: 33831144 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[258]
Terribili R, Grazzini S, Conticini E et al.. “Safety and Efficacy of Long-Term Tocilizumab in a Cohort of Patients with Giant Cell Arteritis: An Italian Monocentric Retrospective Study.” Biologics : targets & therapy (2024). PMID: 39376549 ↗
L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring
[259]
van Sleen Y, van der Geest KSM, Reitsema RD et al.. “Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica.” RMD open (2022). PMID: 39552442 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
[260]
Abhishek A, Iagnocco A, Bijlsma JWJ et al.. “Cross-sectional survey of the undergraduate rheumatology curriculum in European medical schools: a EULAR School of Rheumatology initiative.” RMD open (2018). PMID: 30271621 ↗
L4OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
[261]
de Boysson H, Devauchelle-Pensec V, Agard C et al.. “Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).” La Revue de medecine interne (2024). PMID: 39500637 ↗
L5GUIDELINECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[262]
Régent A, Redeker S, Deroux A et al.. “Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.” The Journal of rheumatology (2016). PMID: 27182063 ↗
L4COHORTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
[263]
Venhoff N, Schmidt WA, Lamprecht P et al.. “Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.” Trials (2021). PMID: 34404463 ↗
L5TRIAL_NONRANDOMCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
[264]
Samson M, Espígol-Frigolé G, Terrades-García N et al.. “Biological treatments in giant cell arteritis & Takayasu arteritis.” European journal of internal medicine (2017). PMID: 29146018 ↗
L5REVIEW_NARRATIVECited in: Immunosuppression Safety & Therapeutic Drug Monitoring
[265]
Martín-Gutiérrez A, Loricera J, Prieto-Peña D et al.. “Tocilizumab monotherapy versus combined in aortitis associated with giant cell arteritis: Factors associated with imaging remission in a multicenter open-label study of 196 patients.” Seminars in arthritis and rheumatism (2025). PMID: 41218409 ↗
L2OTHERCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
[266]
Calderón-Goercke M, Loricera J, Aldasoro V et al.. “Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.” Seminars in arthritis and rheumatism (2019). PMID: 30655091 ↗
L4OTHERCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
[267]
Márquez A, Hernández-Rodríguez J, Cid MC et al.. “Influence of the IL17A locus in giant cell arteritis susceptibility.” Annals of the rheumatic diseases (2014). PMID: 24919468 ↗
L3SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[268]
Russell MD, Schaffer A, Yang Z et al.. “Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY.” The Lancet. Rheumatology (2026). PMID: 42379213 ↗
L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[269]
Chrysidis S, Døhn UM, Terslev L et al.. “Diagnostic accuracy of vascular ultrasound in patients with suspected giant cell arteritis (EUREKA): a prospective, multicentre, non-interventional, cohort study.” The Lancet. Rheumatology (2021). PMID: 38287632 ↗
L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[270]
Cunningham KY, Hur B, Gupta VK et al.. “Plasma proteome profiling in giant cell arteritis.” Annals of the rheumatic diseases (2024). PMID: 39153834 ↗
L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[271]
Ansalone C, McAllister S, Pickerill ES et al.. “Spatial profiling of giant cell arteritis tissues reveals immune heterogeneity and potential predictors of glucocorticoid response.” Annals of the rheumatic diseases (2025). PMID: 41109780 ↗
L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[272]
Borrego-Yaniz G, Márquez A, Estupiñán-Moreno E et al.. “Genome-Wide DNA Methylation Study Reveals Specific Signatures in the Affected Arterial Tissue of Patients With Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 40826980 ↗
L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[273]
Maillet F, Nguyen Y, Espitia O et al.. “Association between large vessel vasculitis and inflammatory bowel disease: a case-control study.” Rheumatology (Oxford, England) (2025). PMID: 39898825 ↗
L3CASE_CONTROLCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[274]
Henderson BA, Mehta VR, Holck P et al.. “Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska.” Arthritis care & research (2025). PMID: 39936239 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[275]
Germanò G, Macchioni P, Possemato N et al.. “Contrast-Enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings.” Arthritis care & research (2016). PMID: 27059104 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[276]
Chu R, Foster C, Ali M et al.. “Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records.” The Lancet. Rheumatology (2020). PMID: 38273631 ↗
L4REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[277]
Carmona FD, González-Gay MA, Martín J. “Genetic component of giant cell arteritis.” Rheumatology (Oxford, England) (2013). PMID: 23843109 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Special Populations, Pregnancy & Fertility
[278]
Kaymakci MS, Berry GJ, Langenfeld HE et al.. “Subclinical aortic inflammation in patients with polymyalgia rheumatica.” Rheumatology (Oxford, England) (2024). PMID: 39024049 ↗
L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
[279]
Watanabe N, Hara Y, Nishito Y et al.. “Tissue degrading and remodelling molecules in giant cell arteritis.” Rheumatology (Oxford, England) (2025). PMID: 39837478 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[280]
Xu S, Jiemy WF, van Sleen Y et al.. “Distinct landscapes of fibroblast subtypes in arteries of patients with giant cell arteritis.” Rheumatology (Oxford, England) (2025). PMID: 40084998 ↗
L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[281]
Nielsen BD, Kristensen S, Donskov A et al.. “Correction: The DANIsh VASculitis cohort study: protocol for a national multicenter prospective study including incident and prevalent patients with giant cell arteritis and polymyalgia rheumatica.” Frontiers in medicine (2026). PMID: 41987771 ↗
L3COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[282]
Bai Y, Wang Z, Zhang C. “Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis.” Open medicine (Warsaw, Poland) (2026). PMID: 41798905 ↗
L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[283]
Robbins D, Khurshid MA, Neil L et al.. “A Delphi survey of patients and clinicians on a unified and stratified approach to managing GCA-PMR spectrum disease.” Rheumatology (Oxford, England) (2026). PMID: 42397190 ↗
L5OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[284]
Colina M. “Beyond clinical criteria: emerging biomarkers and advanced imaging in the diagnosis, monitoring and treatment of vasculitides.” Frontiers in medicine (2026). PMID: 42396140 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[285]
Seidlberger S, Castañeda S, Wietzorrek G et al.. “Plasma proteome differences between giant cell arteritis and polymyalgia rheumatica: a pilot study.” Arthritis research & therapy (2026). PMID: 42387612 ↗
L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Special Populations, Pregnancy & Fertility
[286]
Molina-Collada J, Cowley S, Kirby C et al.. “Prognostic value of quantifying vascular inflammation through ultrasound in patients with giant cell arteritis: the MAGiCUS study.” Rheumatology (Oxford, England) (2026). PMID: 42378435 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[287]
Pacoureau L, Barde F, Seror R et al.. “Association between infection and the onset of giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis.” RMD open (2023). PMID: 37949615 ↗
L3SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
[288]
Robson JC, Kiran A, Maskell J et al.. “The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.” Annals of the rheumatic diseases (2013). PMID: 24095936 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
[289]
Schmidt WA, Moll A, Seifert A et al.. “Prognosis of large-vessel giant cell arteritis.” Rheumatology (Oxford, England) (2008). PMID: 18625659 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related
[290]
Esen I, Jiemy WF, van Sleen Y et al.. “Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis.” Rheumatology (Oxford, England) (2022). PMID: 34730794 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related
[291]
Macchioni P, Boiardi L, Muratore F et al.. “Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study.” Rheumatology (Oxford, England) (2019). PMID: 30517710 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related
[292]
Hill CL, Cole A, Rischmueller M et al.. “Risk of cancer in patients with biopsy-proven giant cell arteritis.” Rheumatology (Oxford, England) (2010). PMID: 20089693 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related
[293]
Martire MV, Cipolletta E, Di Matteo A et al.. “Is the intima-media thickness of temporal and axillary arteries influenced by cardiovascular risk?” Rheumatology (Oxford, England) (2021). PMID: 33547776 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related
[294]
Benichou A, De Gaulmyn M, Guimbretiere G et al.. “Aortitis accelerates the growth rate of thoracic aortic aneurysms.” RMD open (2026). PMID: 42276733 ↗
L3OTHERCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
[295]
van der Veen MJ, Dinant HJ, van Booma-Frankfort C et al.. “Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?” Annals of the rheumatic diseases (1996). PMID: 8733437 ↗
L1RCTCited in: History and Evolution of Treatment
[296]
Atchia I, Brown AK, Chitale S et al.. “Recommendations for rheumatology ultrasound training and practice in the UK.” Rheumatology (Oxford, England) (2021). PMID: 33167033 ↗
L5GUIDELINECited in: History and Evolution of Treatment
[297]
Li L, Neogi T, Jick S. “Mortality in Patients With Giant Cell Arteritis: A Cohort Study in UK Primary Care.” Arthritis care & research (2018). PMID: 29409137 ↗
L3COHORTCited in: History and Evolution of Treatment, Prognosis & Natural History
[298]
Askling J, Klareskog L, Hjalgrim H et al.. “Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.” Annals of the rheumatic diseases (2005). PMID: 15843445 ↗
L3CASE_CONTROLCited in: History and Evolution of Treatment
[299]
Blockmans D. “Why, how and when to look for occult giant cell arteritis in patients with polymyalgia rheumatica.” Rheumatology (Oxford, England) (2025). PMID: 40071419 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[300]
Schmidt WA. “Biopsy vs imaging in the diagnosis of giant cell arteritis. Viewpoint 1: in favour of imaging.” Rheumatology (Oxford, England) (2025). PMID: 40071427 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[301]
Hall S, Persellin S, Lie JT et al.. “The therapeutic impact of temporal artery biopsy.” Lancet (London, England) (1983). PMID: 6139569 ↗
L3OTHERCited in: History and Evolution of Treatment
[302]
Dumont A, Espitia O, Samson M et al.. “Complete PET/CT extinction and subsequent risk of aortic dilation in patients with giant cell arteritis-related large vessel vasculitis treated with tocilizumab.” RMD open (2026). PMID: 41895800 ↗
L4OTHERCited in: History and Evolution of Treatment, Prognosis & Natural History
[303]
Sebastian A, Kayani A, Prieto-Pena D et al.. “Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool.” RMD open (2020). PMID: 33161376 ↗
L4OTHERCited in: History and Evolution of Treatment
[304]
Águeda AF, Monti S, Luqmani RA et al.. “Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis.” RMD open (2019). PMID: 31673416 ↗
L2SR_OBSCited in: Prognosis & Natural History
[305]
Andel PM, Chrysidis S, Geiger J et al.. “Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist.” Rheumatology (Oxford, England) (2021). PMID: 34255830 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
[306]
Czihal M, Köhler A, Lottspeich C et al.. “Temporal artery compression sonography for the diagnosis of giant cell arteritis in elderly patients with acute ocular arterial occlusions.” Rheumatology (Oxford, England) (2021). PMID: 33123722 ↗
L3OTHERCited in: Special Populations, Pregnancy & Fertility
[307]
Andel PM, Diamantopoulos AP, Myklebust G et al.. “Vasculitis distribution and clinical characteristics in giant cell arteritis: a retrospective study using the new 2022 ACR/EULAR classification criteria.” Frontiers in medicine (2023). PMID: 38020143 ↗
L4COHORTCited in: Special Populations, Pregnancy & Fertility
[308]
Lester S, Hewitt AW, Ruediger CD et al.. “PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis.” RMD open (2016). PMID: 27110387 ↗
L5OTHERCited in: Special Populations, Pregnancy & Fertility
[309]
Czihal M, Köhler A, Prearo I et al.. “Hyperechogenic intimal lesions and wall thickness of the temporal and facial arteries in elderly patients with arterial occlusions of the eye.” RMD open (2021). PMID: 34544823 ↗
L4OTHERCited in: Special Populations, Pregnancy & Fertility
[310]
Lee JI, Park JW, Jung Y et al.. “Clinical characteristics and courses of Korean patients with giant cell arteritis: a multi-center retrospective study.” Journal of rheumatic diseases (2024). PMID: 38957359 ↗
L4COHORTCited in: Special Populations, Pregnancy & Fertility
[311]
Gil W, Kodjikian L, Andre M et al.. “Uveitis in Giant Cell Arteritis: A Retrospective Study of Seven Observational Cases and Literature Review.” Ocular immunology and inflammation (2023). PMID: 37815855 ↗
L4COHORTCited in: Special Populations, Pregnancy & Fertility
[312]
Dvir M, Almhanni G, Qaisar H et al.. “When Occipital Artery Biopsy is Preferred to Temporal Biopsy for Giant Cell Arteritis: A Step-By-Step Description of the Surgical Technique.” Mayo Clinic proceedings. Innovations, quality & outcomes (2024). PMID: 38283098 ↗
L5CASE_REPORTCited in: Special Populations, Pregnancy & Fertility
[313]
Jakobsson K, Jacobsson L, Warrington K et al.. “Body mass index and the risk of giant cell arteritis: results from a prospective study.” Rheumatology (Oxford, England) (2014). PMID: 25193806 ↗
L3COHORTCited in: Prevention, Screening & Surveillance
[314]
Wadström K, Jacobsson LTH, Mohammad AJ et al.. “Analyses of plasma inflammatory proteins reveal biomarkers predictive of subsequent development of giant cell arteritis: a prospective study.” Rheumatology (Oxford, England) (2023). PMID: 36255228 ↗
L3COHORTCited in: Prevention, Screening & Surveillance
[315]
Baerlecken NT, Linnemann A, Gross WL et al.. “Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica.” Annals of the rheumatic diseases (2012). PMID: 22228484 ↗
L3OTHERCited in: Prevention, Screening & Surveillance
[316]
Papo M, Friedrich C, Delaval L et al.. “Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case-control and exploratory study.” Rheumatology (Oxford, England) (2022). PMID: 33836046 ↗
L3CASE_CONTROLCited in: Prevention, Screening & Surveillance
[317]
Sverdlichenko I, Xie JS, Lu B et al.. “Atypical Signs and Symptoms of Giant Cell Arteritis: A Systematic Review.” Journal of general internal medicine (2024). PMID: 39482474 ↗
L4SR_OBSCited in: Prevention, Screening & Surveillance
[318]
Makhzoum JP, Baati Y, Tanase O et al.. “Antiplatelet therapy to prevent ischemic events in giant cell arteritis: protocol for a systematic review and meta-analysis.” Systematic reviews (2024). PMID: 38978122 ↗
L5SR_OBSCited in: Prevention, Screening & Surveillance
[319]
Antonini L, Dumont A, Lavergne A et al.. “Real-life analysis of the causes of death in patients consecutively followed for giant cell arteritis in a French centre of expertise.” Rheumatology (Oxford, England) (2021). PMID: 33693495 ↗
L4OTHERCited in: Prevention, Screening & Surveillance

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

Clinical Phenotypes

Classification Criteria

Clinical Significance

Pathophysiology & Mechanism

Effector Mechanisms and Vascular Remodeling

Genetic and Immunometabolic Susceptibility

Treg Dysfunction and the IL-6 Axis

Persistence of Vascular Disease

Epidemiology, Etiology & Risk Factors

Temporal Trends

Risk Factors

Seasonal Variation

Genetic and Clonal Drivers

Clinical Presentation

Presenting Symptoms

Neurological and Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria

Imaging

Temporal Artery Biopsy (TAB)

Laboratory Studies

Classification Criteria: 2022 ACR/EULAR

Diagnostic Algorithm

Controversies and Guideline Disagreement

Key Points

Severity, Disease Activity & Risk Stratification

Treat-to-Target and Definitions of Disease Activity

Composite Activity Scores and Imaging Biomarkers

Predictors of Relapse and Treatment Failure

Damage Accumulation and Prognosis

Acute Management: Flares & Organ-Threatening Disease

Step 1: Initial Assessment and Severity Classification

Step 2: First-Line Intervention for Acute Flare and Organ-Threatening Disease

Step 3: Second-Line Interventions for Refractory or Relapsing Flares

Step 4: Monitoring and Titration

Step 5: Resolution and Transition to Long-Term Management

Controversies and Guideline Disagreement

Long-term Management: The DMARD Ladder & Treat-to-Target

Step 1: Identify Candidates for a Glucocorticoid-Sparing Agent

Step 2: First-Line DMARD, Methotrexate or Tocilizumab?

Step 3: Second-Line and Refractory Disease

Step 4: Duration of Therapy and Tapering

Step 5: Monitoring and Treat-to-Target

Drug / Modality Comparison Table

What NOT to Do

Controversies and Guideline Disagreement

Immunosuppression Safety & Therapeutic Drug Monitoring

Pre-Biologic Screening

Ongoing Lab Monitoring

Infection Prophylaxis

Perioperative Management

Therapeutic Drug Monitoring

Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)

Cranial and Ocular Involvement

Large-Vessel Involvement

Cardiovascular and Cerebrovascular

Other Organ Systems

Complications: Disease-Driven & Treatment-Related

Disease-Driven Complications

Treatment-Related Complications

Prevention and Monitoring

History and Evolution of Treatment

The Glucocorticoid Era

Failed Biologic Pathways

The Tocilizumab Revolution

Other Promising Agents

Prognosis & Natural History

Relapse and Remission Patterns

Mortality

Step 5: Resolution and Transition to Long-Term

Perioperative

The Revolution